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 Longitudinal assessment of nutritional status and its effects on the 
outcome of children completed treatment for Acute 
Lymphoblastic Leukaemia 
 
Magdalenal R, Sarah M, Narendra C, Deepthi B, Leni G Mathew. 
 
Introduction:  
The event free survival of children with acute lymphoblastic leukaemia (ALL) has 
increased substantially in the last two decades. Several authors have published the potential 
impact of nutritional status on the treatment outcome. Studies have shown that both under-
nutrition and obesity affects the outcome in children with ALL.  
A high prevalence of obesity has also been increasingly recognized in survivors of paediatric 
ALL. Paediatric cancer survivors have increased risk of obesity, hypertension, dyslipidaemia, 
and type 2 diabetes, leading to premature cardiovascular disease (CVD). 
 
Key words:  
ALL, Malnutrition, outcome, obesity in survivors, metabolic syndrome 
 
Objectives: 
1) To assess the nutritional status of children with ALL at diagnosis and at two points during 
treatment (i.e starting of delayed intensification and maintenance), end of treatment and 
annually after completion of treatment.  
 
2) To study the impact of nutritional status on various outcome parameters such as early 
response to treatment, time taken for induction remission, number of febrile neutropenia 
episodes, relapse and death.  
 
3) To study the prevalence of overweight and obesity in children with ALL on follow up after 
completion of therapy.  
 
4) To study the prevalence of hypertension, dyslipidaemia and glucose intolerance among 
overweight and obese children with ALL after completion of therapy.  
 
Materials and Methods: 
            Data from medical records of 241 children with ALL was retrieved during the study 
period. Patient’s demography, risk stratification, treatment received, complications, outcome 
and follow up visit information were collected .Weight and height were available  at 
diagnosis, during treatment, at the beginning of delayed intensification and maintenance 
phase as well as at end of treatment. BMI was calculated and only 227 children were grouped 
according to nutritional status as 14 children were less than 2 years of age at diagnosis. 34 
children died and 195 completed treatment.The change in the nutritional status was analysed 
throughout treatment and post treatment during follow up. Treatment outcome was also 
compared between the nutritional groups. Children who were overweight/obese on follow up 
were further evaluated for early signs of metabolic syndrome. 
 
 
 Results: 
          241 children treated for Acute Lymphoblastic Leukaemia (ALL) were included in this 
study on longitudinal assessment of nutritional status from diagnosis, through treatment and 
post treatment period using BMI charts. 
        At diagnosis, 44% of children were under nourished, 47 % were well nourished and 9% 
were overweight/ obese. At end of treatment 13% were undernourished and 29% were obese. 
While there was a significant reduction in the number of children in the under nourished 
group, the proportion of obese children increased significantly from 7% at diagnosis to 29% 
at the end of treatment. This was statistically significant (p<0.05). The impact of nutritional 
status on treatment response and outcome did not show statistical significance.  
         114 children were reviewed during this study period; 30(26%) overweight/obese 
children were identified. This group was further screened for metabolic syndrome. The 
prevalence of hypertension was 13%, dyslipidaemia was 27% and glucose intolerance was 
7% in the above study group.  
 
Conclusion: 
            Nutritional status of children treated for ALL change from diagnosis, through treatment and 
post treatment period. In our study, it was noted that the prevalence of under nutrition reduced 
considerably as they went through treatment. Also significant proportion of well-nourished children 
became obese by the end of their treatment. In this group of obese/overweight children many had 
hypertension, dyslipidaemia and glucose intolerance. Hence nutritional status of children on 
treatment for acute lymphoblastic leukaemia be monitored closely during and after treatment. Early 
signs of metabolic syndrome should be addressed and lifestyle modification should be suggested. 
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INTRODUCTION 
 
Successive international clinical trials and improvement in supportive care has led to 
substantial improvement in the event free survival of children with acute lymphoblastic 
leukaemia (ALL) in the last few decades. There is increasing focus on better risk 
stratification, decreasing toxicity of treatment by reducing treatment for good risk patients, 
early identification and management of late effects of treatment. 
Though nutritional status of a child at diagnosis is not a criterion for risk stratification, 
several authors have published its potential impact on the treatment outcome. Studies have 
shown that both under-nutrition and obesity affects the outcome in children with ALL. The 
various adverse effects of malnutrition
1-6
 have been delayed remission induction, increased 
risk of infection leading to prolonged hospital stay and cost, increased risk of relapse, 
decreased tolerance to chemotherapy, increased toxicity and reduced event free survival 
(EFS). 
There is also continued effect of the treatment in survivors leading to obesity and 
subsequently to metabolic syndrome. These are due to multifactorial reasons like anti-
neoplastic drugs, steroids and radiation. 
Our study has looked at the nutritional status of children with ALL at diagnosis and 
two time points during treatment (at the start of delayed intensification and maintenance), end 
of treatment and annually after completion of treatment. Outcome variables analysed in this 
study included early response to treatment, time taken for induction remission, number of 
febrile neutropenia episodes, relapses and death. Children who were on follow up during the 
study period were assessed for their nutritional status. Those who were overweight/ obese 
were further evaluated for early signs of metabolic syndrome.  
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AIMS AND OBJECTIVES 
 
1) To assess the nutritional status of children with ALL at diagnosis and at two points during 
treatment (i.e starting of delayed intensification and maintenance), end of treatment and 
annually after completion of treatment 
 
2) To study the impact of nutritional status on various outcome parameters such as early 
response to treatment, time taken for induction remission, number of febrile neutropenia 
episodes, relapse and death. 
 
3) To study the prevalence of overweight and obesity in children with ALL on follow up 
after completion of therapy.  
 
4) To study the prevalence of hypertension, dyslipidaemia and glucose intolerance among 
overweight and obese children with ALL after completion of therapy.  
 
 
  
 
 
                 
 
10 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
 
 
 
 
 
 
11 
 
REVIEW OF LITERATURE 
  
Acute Lymphoblastic Leukaemia (ALL) is the most common cancer in children and it 
accounts for 25% of all childhood malignancies
4
.Survival rates of ALL has improved dramatically 
since 1980. Improvement in risk stratification strategies, large clinical trials and good supportive care 
has led to the success story of ALL. The significance of nutritional status in children with ALL is 
related to its possible influence on the course of the disease, tolerance of chemotherapy, infection 
rates, clinical outcome and survival. Malnutrition is a well- known health problem in our country. 
The outcome of treatment in ALL depends not only on the biological diversity of the leukemic cells 
but also on the individual variability of drug metabolism and the nutritional status of the child at 
presentation and it has been noticed that both under-nutrition and obesity have adverse effects on the 
treatment outcome of children with ALL. 
 
Relevance of Nutritional status in  children with ALL  
 
  
On an average, the prevalence of under-nutrition in ALL at diagnosis is 50% in developing 
countries
8,9
 and the prevalence of obesity at diagnosis is 8.6%
6
.  
 
Children, cancer and nutrition form a dynamic triangle. Impact of malnutrition in ALL 
children is multifactorial. The important aspect is the identification of a risk factor that is amenable to 
intervention. In contrast to most of the prognostic factors, weight is an important factor that can be 
modified by interventions. The importance of nutritional status in children with cancer is due to its 
possible influence on the course of the disease and survival. Some have attributed it to decreased 
tolerance of chemotherapy, altered metabolism of anti-neoplastic agents and high infection rates in 
malnourished children
8
. 
12 
 
In children who are malnourished at diagnosis, it was found that chemotherapy is more toxic 
and less effective compared to those found with adequate nutritional status
11
. Under-nutrition is 
negatively associated with therapy related toxicities. 
The adverse effect of under-nutrition on treatment is a result of changes that include 
difference in drug absorption, transportation and decreased hepatic metabolism due to lack of 
enzymatic activity by cytochrome P 450
11
. 
The increased susceptibility to infections is related to the dysfunction of the immune status in 
these patients. Adipose tissue plays an important role as a facilitator in the pharmacokinetics of anti-
neoplastic drugs. This tissue is structurally and functionally altered in malnutrition. This decreases 
the effectiveness of anti-neoplastic drugs and increases the toxicity-both of which are deleterious to 
the children during the course of treatment.
12 
The effect on malnutrition on Event free survival (EFS) 
is also probably due to pharmacokinetic variations which in turn has an impact on the 
pharmacodynamics of the drugs. 
Both under or overweight has potential epigenetic influence and nutritional insufficiencies can 
lead to up-regulation or down-regulation of various   genes
13 
Mechanism of under nutrition  
Children with cancer experience lot of energy imbalance
8
. There are changes involved in 
carbohydrate, fat and protein metabolism leading to malnourishment.  
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Changes in the metabolism of fat, glucose and amino acids (AA) induced by the presence of the 
tumour is shown below: 
There is increased lipid breakdown and increased protein turn over resulting in weight loss. 
These children have high caloric expenditure. They utilise both dietary glucose and glucose from 
gluconeogenesis and from amino acids. Glucose is converted to lactate which is recycled by liver 
with lot of energy expenditure. Release of Cachectin and TNF leads to decrease in  total body fat..  
                                                      DIET 
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There is also the other end of the spectrum –overweight and obesity. Obesity at diagnosis is  
associated with high risk of obesity at the end of treatment and survivorship. 
 
Effect of under nutrition on treatment outcome  
Mendizabal et al
1
 showed that children who presented with malnutrition at diagnosis had 
significantly worst outcome than well-nourished children in terms of disease free survival and 
relapse. Forty three paediatric patients with standard risk ALL were studied. Of the 43 patients 37% 
presented with malnutrition at diagnosis. The 5 year disease free survival (DFS) was 83% in well-
nourished and 26% in undernourished children (p < 0.001). Relapses were more frequent in bone 
marrow in undernourished group than the well- nourished group, 56% Vs 7% (p< 0.0001). 
Begum et al
2
 compared the outcome of undernourished children versus well-nourished 
children with regard to induction of remission. This prospective study included 60 children with 
ALL, between 1-15 years of age. Groups were divided based on weight for age. Thirty children were 
undernourished and thirty were well-nourished. It was found that the number of days required to 
achieve remission in the under nourished children were longer (39±0.72 days Vs 31.63±0.17 days) 
and statistically significant (p < 0.04). 
  A multivariate analysis by Viana et al
3
 looked at the influence of nutritional status with the 
probability of overall survival and duration of first complete remission in 128 children treated for 
ALL. It was found that weight for age z score of < -2 was a poor prognostic factor.  
Roy et al
4
 did a retrospective analysis in 159 children with ALL, to assess the influence of 
malnutrition on treatment tolerance, treatment related complications and treatment outcomes during 
induction and maintenance. Haematological toxicity was more in severely malnourished children. 
15 
 
Remission rates were less and relapse rates were proportionately more in malnourished children. 
Thirty children were severely malnourished. The incidence of febrile neutropenia was significantly 
higher in severely malnourished children than well- nourished children (Mean 3.8vs1.42, p< 0.001).  
Hafiz MG et al
5
 Conducted a prospective study to evaluate the nutritional status at initial 
presentation and to correlate the effects of nutrition on induction of remission. This was conducted in 
Dhaka, Bangladesh during period of 1 year from July 2006 to June 2007.66 children were diagnosed 
between period of 1 year from 1-15 years irrespective of sex. Thirty five (53.03%) children were 
under- nourished and thirty one (46.97%) were well nourished. The under nourished children during 
induction had culture proven/clinically documented infections 2-3 times more frequently than well 
nourished children. They also required longer duration of induction (p<0.001) and prolonged period 
of hospital stay (p<0.001). 
Mejia-Arangure et al
14
 conducted a prospective study in children with ALL. They included 
163 patients  below 16 years of age. Nutritional groups were made based on weight/height 
(waterlow’s classification). In the malnourished group 46% completed treatment and were alive, 
9.8% had relapse, 45% died whereas in the well -nourished group 59% completed treatment and were 
alive, 21.3% relapsed and 19% died. The risk of death during initial phase of treatment was 2.6 times 
higher in the malnourished group than the well -nourished group despite lower relapse rate. The risk 
of death increased with increasing severity of malnutrition. 
Previous studies have shown the influence of weight at the time of diagnosis on event-
free survival (EFS) and treatment related toxicity (TRT) in childhood ALL. More recently 
Orgel et al
15
 from the Children’s Oncology Group correlated outcomes to the duration of 
weight extremes during treatment for paediatric acute lymphoblastic leukaemia (ALL). The 
authors evaluated the prognostic implications of weight extremes during intensive phase of 
therapy  for ALL. A total of 2,008 children who were treated for high risk ALL in the 
16 
 
Children’s Oncology Group study CCG-1961, were included in the study. The effect on EFS 
and TRT (treatment related complication) of extreme weight (either obese or underweight) at 
diagnosis and cumulative time with an extreme weight between end of induction and start of 
maintenance therapy was analysed. Obese and underweight patients had 5 year EFS rate of 
64%±3% and 65%±5%,respectively,as compared with 74%±1% for normal/overweight 
patients (univariable P = 0.002) 
 
Analysis of EFS was done from the start of maintenance for 1,581 patients alive and 
disease free at that time. There were 644 patients (40.7%) who had extreme weight (393 
obese   and 251 underweight), whereas 937 patients (59.3%) were normal/overweight during 
their treatment. Children who were either obese or underweight had inferior EFS as compared 
with those who did not have extreme weight (univariable P=0.008).  If children were obese or 
underweight for >50% of their treatment time, EFS was 73%±3% and 70%±5% respectively. 
The EFS for children who were obese or underweight for  < 50% of the time during treatment 
was  77% ± 3% and 82% ±3%, respectively. 
 
This study showed that patients who presented obese or underweight and remained so 
for ≥ 50% of the pre maintenance phases ((≥ 50% obese: HR, 1.43; 95% CI, 1.04 to 1.96 and 
≥ 50% underweight (HR, 2.30; 95% CI, 1.46 to 3.63; global P < .001) had the greatest risk of 
an event. In contrast children who presented obese or underweight but normalised their 
weight for > half of pre maintenance therapy had similar risk in comparison to children who 
were never obese or underweight. There was a protective effect noticed for those who started 
in the normal weight category at diagnosis but became underweight for < half the pre 
maintenance period (HR, 0.52; 95% CI, 0.32 to 0.83).When further analysed, BMI at 
diagnosis and BMI as a continuous linear-quadratic element, the cumulative time–spent effect 
17 
 
remained significant at P ≤ .004, which shows that the effect was not attributable to 
differences in the distribution of weights at presentation. 
 
There was statistically significant association between weight category and risk of 
grade 3 and 4 toxicity (higher rates of TRT at both extremes of weight; P =0.008) during 
13946 courses of treatment among 2008 high risk patient cohort. There was also a risk profile 
of toxicity which was specific to weight category. Hepatic and pancreatic toxicities were 
more common among obese patients both P <0.001. In contrast, pulmonary toxicity and 
fungal infections were more common among P =0 .001 
 
Underweight children also had more severe hematologic toxicity, as evidenced by the 
use of more hematologic support P <0 .001, including blood product transfusion and the use 
of hematopoietic growth factors. 
 
Effect of obesity/ overweight on treatment outcome 
There are very few studies that looked at the treatment outcome in children with obesity at the 
time of diagnosis. In a recent study by Aldhafiri et al
16
> 40% of all patients were underweight, 
overweight or obese at diagnosis. A retrospective analysis was done by Butturini et al
6 
in 4260 ALL 
children enrolled between 1988-1995.Three hundred and forty three (8%) children were obese. The 5 
year EFS (event free survival) in obese Vs non obese children was 72±2 Vs 77±0.6( p 0.02).The 
relapse rate was also higher in the obese group 26±2.4Vs 20±0.6( p 0.02). But this association was 
not seen in patient younger than 10 years. The poor outcome in both univariate and multivariate 
analysis in obese children was significant for children > 10 years of age at diagnosis.  
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Nutritional status following completion of treatment 
 
Childhood leukaemia survivors are at risk for several possible late effects of the disease or 
treatment. Obesity can be considered one of the most important health conditions in patients treated 
for childhood cancer, especially in ALL survivors. In paediatric ALL, the rate of obesity ranges 
between 40-50% from the end of treatment to 5 year post treatment.
17-20 .
 Hence, survivors of ALL 
are prone to develop metabolic co-morbidities like dyslipidaemia, insulin resistance and 
hypertension. It is also found that overweight patients when diagnosed to have leukaemia after 10 
years of age had low mean 5 year EFS(event free survival) and increased risk of relapse than normal 
weight patients
6
. 
There are many studies which have analysed the long-term prevalence of obesity in childhood 
after the end of ALL treatment. Table below shows various studies where children have been 
followed up from minimum of 4 years till adulthood after completion of ALL treatment. The rate of 
obesity ranges between 40-50% from the end of treatment to 5 year post treatment. Odame et al
21
 
followed children for 4 years after treatment and found that the prevalence of obesity was more in 
girls (57%) than in boys(21%). Jarfelt et al
27
 followed up patients for a minimum of 15 years and 
reported a prevalence of 34%. 
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AUTHOR NUMBER OF 
PATIENTS 
ASSESSMENT 
TIME 
PREVALENCE 
OF OBESITY (%) 
Odame et al 
21
 40 Diagnosis +4 years 57 girls 
21 boys 
Van Dongen 
 
Melman et al
22
 
 
113 Diagnosis +4 years 24 
Talvensaari et al
23 
 
50 Diagnosis +13 years 32(vs 10 in controls) 
Reilly et al
24 
98 Diagnosis +3 years 16 
Nysom et al
25 
95 Diagnosis +11 years 25 
Meacham 
 et al
26 
1665 Adulthood 18 girls 
16.5 boys 
Jarfelt et al
27 
35 20(minimum 15 yrs) 34 
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 Mechanism of obesity in children in the post treatment period       
Being overweight/obese at the time of diagnosis and excessive weight gain during treatment 
were significant predictors of being overweight/obese after treatment. Weight at diagnosis has an   
influence on the weight gain during and at the end of treatment
28
. Excessive weight gain during 
treatment is unlikely to be reversed after completion of treatment. 
 There are various factors implicated in increase weight gain after successful treatment for ALL                   
 Cranial irradiation  
 Specific chemo related complications 
 Steroid use 
 Growth hormone deficiency 
 Role of leptin 
 Theory of premature adiposity rebound(AR) 
 Lifestyle changes 
Cranial radiation increases the risk of obesity in survivors29 
Craig et al
30
 reported the effect of radiation on CNS and its association with gender and dose of 
radiation during treatment.  The study determined the effect on BMI Z score at final height of age at 
diagnosis, sex and the radiation dose that was given. Patients were divided based on the sex and 
radiation dose, 18-20 Gy and 22-24 Gy. There was increase in BMI Z score at final height for female 
children who received a dose of 18-20 Gy. Recent study by Khan RB et al
31 
have shown that upto 
83% of long term survivors of ALL have increased neurological morbidity and decreased quality of 
life. 
21 
 
Drugs  
Vaisman et al
32
 showed the effect of specific chemotherapy agents like Methotrexate and  
Mercaptopurine  to have an effect on metabolic fuel use and protein synthesis and turnover. 
 
Mechanisms of development of metabolic syndrome due to various chemotherapy agents are listed 
below. Other than these, Actinomycin, Bleomycin and platinum drugs used for treatment of other 
tumours also contribute to obesity in children.  
 
Drugs Metabolic effect 
Alkylators Obesity, Dyslipidaemia, Steatosis, Insulin resistance,  
Hypertension, Impaired glucose flux into liver. 
Anthracyclins Obesity, Dyslipidaemia, Steatosis, Insulin resistance,  
Hypertension, Metabolic endo-toxemia. 
Anti-metabolites Adiposity, Atherosclerosis, Steatosis, 
Insulin resistance, Impaired glucose flux into liver, 
Metabolic endo-toxemia 
Vinca Alkaloids Hypertension, Hyperglycaemia, Altered liver glucose 
Metabolism, Steatohepatitis, Increased calorie absorption. 
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Corticosteroids 
Corticosteroids are well known for their effect on weight gain. They lead to obesity by 
various mechanisms- effect on appetite, regulation of energy intake, alteration in substrate oxidation, 
alterations in energy expenditure, increased adiposity due to suppression of growth hormone and 
resistance to leptin. 
The end organ effect of chemotherapeutic agents and steroids and its mechanism in metabolic 
syndrome have been extensively given by Rosen et al
29 
Many tissues involved in lipid metabolism and glucose homeostasis are affected by chemotherapy. 
Treatment for ALL has adverse effect on various tissues/organs which leads to increase in risk factors 
of metabolic syndrome like obesity, insulin resistance, dyslipidaemia, atherosclerosis and 
hypertension. This in-turn is responsible for the outcomes like Type 2 diabetes, cardiovascular 
disease etc.  
CANCER THERAPY 
 
Adverse effect on bone, muscle, GI, adipose, liver, endothelium 
 
Increase in risk factors for metabolic syndrome 
 
Development of metabolic syndrome 
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Bones: 
Bones play an essential role in metabolic health. Osteocalcin is an osteoblast specific protein 
that promotes beta cell proliferation and insulin secretion-this improves insulin sensitivity. This 
protein is low in children undergoing cancer chemotherapy. Low osteocalcin is predictive of insulin 
resistance. Both chemotherapy and radiotherapy leads to depletion of osteogenic precursors and 
osteoblasts.It also has adverse effect on osteoblast activity. High dose of steroids cause bone loss 
which is persistent and osteonecrosis. Avascular necrosis is a major adverse effect of steroids on the 
bone. 
 
Muscle: 
Steroids impair the synthesis and breakdown of muscle protein. Drugs like Vinca 
Alkaloids disrupt the functional integrity of microtubules. Survivors are unable to maintain 
body composition as there reduced muscle mass, decreased sarcolemma surface area and 
decreased resting thermogenesis. Muscle mass is reduced by various mechanism like 
decreased physical activity during treatment and motor neuropathies. Decreased sarcolemma 
surface can lead to overt type 2 diabetes by decreasing whole body insulin-stimulated glucose 
uptake. As the microtubules are destroyed there is decreased glucose uptake and transport by 
skeletal muscles due to GLUT 4 vesicle translocation. This   pathology in the skeletal muscle 
predisposes to atherogenic dyslipidaemia.  
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GIT: 
Certain chemotherapy agents decrease gut motility and affects the constitution of microbiota. 
Before development of obesity, there is change in the composition of the gut microbiota. Use of 
broad spectrum antibiotics leads to changes in the gut flora. This leads to modification of the gut 
flora. Physical disruption of the gut barrier leads to leakage of lipopolysaccharides (LPS) into the 
blood. This acts as a trigger for the development of metabolic endotoxemia which is in turn a risk 
factor for atherogenesis and insulin resistance. 
Liver: 
Alkylators, anti-metabolite etc are known to cause SOS- Sinusoidal obstruction syndrome. 
Glycogenesis, lipogenesis, fatty acid oxidation, mitochondrial oxidation and oxidative 
phosphorylation are affected. When cells cannot oxidise fatty acid ,they are exported leading to 
dyslipidaemia. Survivors are also prone for focal nodular hyperplasia.
33
 
Adipose tissue: 
Adiponectin which regulates lipid and glucose metabolism id reduced is decreased 
leading to endothelial damage and atherosclerosis.  
 
Endothelium: 
Chemotherapy affects endothelial function by disrupting the nitric oxide (NO) pathway. 
Certain drugs causes increase in production of oxygen free radicals leading to oxidative stress. This 
uncouples endothelial nitric oxide synthase, resulting in production of superoxide anion rather than 
vasodilator (NO). This causes arterial stiffness and hypertension in childhood cancer survivors. 
Endothelial function assessed by flow-mediated dilation has been shown to be associated with 
development of diabetes. 
25 
 
Role of leptin in obesity 
Mechanism that explains the relation between cranial radiation therapy and obesity is leptin 
insensitivity.
35
 Leptin
34,36
 is a hormone derived from the adipocytes .It binds to the biologically active 
form of its receptor (LEPR) in the hypothalamus. Radiation-induced damage of this axis could 
possibly disrupt the leptin signal and lead to obesity. As very few survivors developed this 
complication leptin receptor polymorphism
35
 particularly to LEPR GlnQ223Arg was suspected as 
cause of obesity in female survivors.  
Adiposity rebound in obesity 
Adiposity rebound (AR)
37
 -“is the point at which BMI increases after its nadir in childhood”. 
The nadir of AR coincides with peak occurrence of ALL. Hence AR is a crucial period in the 
development of obesity. Younger age of onset of AR is an increased risk of high BMI and 
development of obesity.  
Life style changes  
During chemotherapy there is a major change in the lifestyle of the patient. Loss /decreased 
physical
20,28
 activity occurs during hospitalization. Factors taken into account for decreased physical 
activity includes diminished interest, over protectiveness of the care takers, steroid related myopathy 
and Vincristine related neuropathy. It has been found that even after treatment there is reduced 
physical activity in survivors of malignancy than the normal healthy siblings. 
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OBESITY INTERVENTIONS 
 Interdisciplinary family 
centered programs for 
behavioural, dietary, 
and physical activity 
changes 
 Electronic media 
intervention 
 Pharmacologic 
intervention, surgery( 
hypothalamic obesity) 
Optimal Weight 
      CAUSES 
 Growth hormone deficiency  
causes hypothalamic pituitary 
axis damage 
 leptin deregulation 
 Premature adipose rebound 
 Exposure to corticosteroids 
 Reduced physical activity 
 Poor dietary habits 
 
CONSEQUENCES 
 Increased treatment related 
mortality 
 Increased risk of relapse 
 Decreased overall survival 
 Childhood obesity and its 
associated comorbidities 
 Risk of second cancers 
in.survivorship and adulthood 
 
Major causes and consequences of obesity in childhood cancer patients and /or 
survivors with recommended interventions
34
 are given as follows 
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Obesity /overweight in children completed treatment of ALL  
Zhang et al
38
 evaluated the longitudinal changes in the rate of obesity and BMI z –scores in 
ALL children during and after their treatment for cancer. This was a retrospective study which 
involved paediatric ALL patients treated between 1985-2010 at Floating Hospital for Children at 
Tuft’s Medical Centre. It included patients < 21 years with Pre-B ALL (Standard or high risk) or T- 
cell ALL (high risk).There were 83 patients finally included in the study. The longitudinal weight 
changes showed that 20.5% were overweight and 10.8% obese at diagnosis, by the end of induction 
41% were overweight/obese. However there was a decrease at end of consolidation where 25.3% 
were overweight/obese. There was an increase in BMI again at during the first 6 months of 
maintenance (39.7%).The number of children who were overweight/obese at the end of treatment and 
5 year post follow up was 38.2% and 40.5% respectively. Of these, 81.3% remained 
overweight/obese at the end of treatment and 66.7% remained overweight /obese 5 years post 
treatment. This shows that children with ALL are at increased risk of becoming overweight /obese 
early in treatment. Increases in weight are maintained throughout and after treatment. This study 
clearly shows that high BMI z- score at diagnosis was associated with an increased risk of being 
overweight /obese at treatment completion (odds ratio=2.9,95% CI:1.6-5.1).Weight gain during 
treatment was associated with being overweight /obese 5 years post treatment (odds ratio=3.8, 95% 
CI: 1.1-12.5). Thus this study shows that the status of weight /BMI z-score at the time of diagnosis is 
a significant predictor of being overweight/obese at the end of treatment. This emphasises that 
intervention should be undertaken to control weight during early treatment –especially for children 
who are overweight /obese at the start of treatment. 
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Obesity and hypertension are well known in survivors of ALL. Elevated parental BMI was 
associated with elevated BMI at diagnosis. A study by Esbenshade et al
39
 in 183 patients with 
paediatric ALL diagnosed during 2000-2008 analysed the changes in BMI and blood pressure over 
the course of treatment of ALL. This was a retrospective cohort ranging from 1-21 years at diagnosis 
.These children were diagnosed as standard or high risk Pre-B ALL/T- cell ALL .The Children’s 
Oncology Group (COG) protocol was followed. The BMI z- score showed an increase (P<0.001) 
from induction to consolidation then decreased (P < 0.001)at the start of delayed intensification. BMI 
was again found to increase during early part of maintenance. Blood pressure analysed showed that 
31.1% had systolic pre-hypertension and 18.6% had diastolic pre-hypertension during the course of 
therapy.41.5% had systolic hypertension and 24% had diastolic hypertension. 
Study by Withycombe et al 
10
 in 1638 patients between 1996-2002 also found that treatment 
of high risk childhood ALL was associated with excess weight gain from the beginning of 
maintenance through the end of treatment. By the end of treatment 23% were obese, compared with 
14% at diagnosis. Mean BMI % remained high throughout treatment for those who were obese at 
diagnosis. Thus high prevalence of obesity poses a challenge for paediatric oncologist. It has to be 
approached and addressed effectively through multidisciplinary approach. There is a need to assess 
changes in BMI at several points from diagnosis until several years after completion of treatment.  
Central obesity has a very important implication regarding health as it is an adverse effect in 
children. Hence methods to measure central obesity is needed for early intervention. Waist 
circumference is an alternative to the measurement of BMI in terms of defining adiposity. Waist 
circumference (WC) is measured with a non-stretchable tape by trained nutritionists (exerting the 
same standard pressure on the tape) at the midpoint of the lowest rib cage and the iliac crest, to the 
nearest 0.1 cm in a standing position during end-tidal expiration. 
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Taylor et al
40
 compared WC, waist hip ratio(WHR) and conicity index to see which one was 
significantly better to determine trunk fat mass. This study has demonstrated that WC is a simple 
method that can be used for screening high central adiposity. 
Study by Kurian R et al
41
 provides reference values and percentile curves for waist 
circumference and Wt /Ht ratio of urban Indian children. It has been suggested that the 75th 
percentile of waist circumference from the study can be used as an “action point” for Indian 
children to identify obesity and help in early intervention. 
Waist circumference has been very well correlated with other metabolic syndrome 
parameters like blood pressure, lipid profile , fasting blood glucose and fasting insulin levels 
in normal children. Zhang YX et al
42
 has shown the prevalence of high blood pressure with 
high WC percentile among normal children and adolescents. This study showed included 
6895 children(3453 girls and 3442 boys)- whose age ranged between 7-17 years. There was 
increase  of 5.4 times and 2.4 times (in boys and girls respectively )in blood pressure when 
the WC was > 95
th
 centile. 
A cross sectional study
43
 was done on 188 healthy obese children between 7-11 years 
to determine where routine assessment of waist circumference has predictive value for 
developing cardiovascular risk factors and diabetes mellitus. ≥ 90th centile was taken as high 
waist circumference .Children with high WC had low High density cholesterol (HDL), high 
Triglycerides(TG) and increased fasting glucose level, indicating that high waist 
circumference correlates with high risk of insulin resistance and dyslipidaemia.
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Summary 
 
Review of literature has clearly illustrated the importance of nutritional status assessment, 
mechanisms of both under and over nutrition and its effect on overall health of cancer survivors. Both 
underweight and overweight in children with cancer is not desirable. Optimum nutritional status is 
required to cope with the demands of the disease and its long term treatment effects. Nutrition thus 
becomes one of the fundamental parts of care of children with cancer and should be recognised as 
crucial step in cancer treatment. Appropriate and adequate nutrition is needed to maintain optimal 
growth and development. This will in-turn enhance the survival out-come, decrease the toxicity and 
improve the quality of life in these children. 
Based on this information, we carried out this study on longitudinal assessment of nutritional 
status of children with ALL and its effect on outcome and quality of life.  
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MATERIALS AND METHODS 
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MATERIALS AND METHODS 
 
Data retrieval  
 
Data from medical records of  241 children with ALL  was  retrieved during the study period. 
Patient’s demography, risk stratification, treatment received, complications, outcome and follow up 
visit information were collected by the investigator. Weight and height were available for children at 
diagnosis, during treatment - at the beginning of delayed intensification and maintenance phase as 
well as at end of treatment. Following completion of treatment children are followed up once in 3 
months in the first year , twice in the second year and annually thereafter  till the 5
th
 year. 
 
 Inclusion criteria: Children completed treatment for ALL by July 2014 
 
Exclusion criteria:  Children not yet completed maintenance phase of treatment  
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Risk stratification of children with ALL was used based on international guidelines, with minor  
modifications. 
Factors Standard risk 
 
Intermediate risk 
 
High risk 
Age in years >1,<10 <1,>10  
WBC/cumm <20,000 >20,000 >1,00,000 
IPT Pre B ALL T cell ALL T/Pro B ALL  
Cytogenetics t(12;21) t(1;19) t(9;22),t(4;11) 
CSF Negative  positive  
Testes Negative positive  
Prednisolone 
 response 
PGR PGR PPR 
BMA M1 M2 M3 
 
PGR- Prednisolone good response-day 8 peripheral blood absolute blast count should be < 1000. 
PPR- Prednisolone poor response 
Bone marrow aspirate (BMA)       M1 blasts < 5% 
                                                      M2 blast 6-25% 
                                                      M3 > 25% blast 
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Treatment 
 Once they are stratified, treatment is instituted based on their risk group. Outline of treatment is 
shown here. Details are available in Annexure no 1. 
TREATMENT 
 
Pre- induction 
 
Induction 
 
Consolidation 
 
Interim Maintenance 
 
Delayed intensification 
 
Maintenance 
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Assessment of nutritional status of children  
Using weight and height, BMI was calculated for children older than 2 years of age at 
diagnosis and they were divided into under nourished, well-nourished or overweight/obese. Outcome 
parameters such as response to treatment, number of febrile episodes, overall survival and event free 
survival were compared between these groups.  
Height was measured to the nearest millimetre with a wall mounted Harpenden Stadiometer. 
Weight was measured with electronic scales to the nearest 0.1 kg. BMI (kg/m2) was calculated.  
Waist circumference was measured (cm) in duplicate with an anthropometric tape while the subjects 
were wearing light clothes.  
Body Mass Index(BMI) = Weight(kg) / Height(m)
2
 .BMI centiles were calculated using the US 
Centre for Disease Control and Prevention program for children between 2 and 20 years of age 
(http://www.cdc.gov/growth charts) 
 
Children’s nutritional status  classified based on BMI using CDC growth charts is as follows 
         
Undernourished children    < 5
th
 centile 
         Well-nourished children   5-85
th
 centile 
         Overweight children                > 85
th
 centile but < 95
th
 centile
 
          Obese children                       ≥ 95th centile 
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Screening for metabolic syndrome: Overweight /obese children were evaluated further for early 
signs of metabolic syndrome by measuring waist circumference, lipid levels, HbA1C, blood insulin 
and sugar levels. Tanner’s staging was also looked at. Parents’ weight and height were also 
measured and their BMI was calculated. This data was compared with children’s nutritional status.  
Glucose insulin ratio (GIR)  It is the ratio of fasting glucose level and fasting insulin level. 
DEFINITION OF THE OUTCOME VARIABLES IS AS FOLLOWS: 
1. Early response to treatment: The early response to treatment is based on day 8 blast count after 7 
days of prednisolone 60 mg/m
2
/day with or without intrathecal Methotrexate. The response to 
treatment is good  prednisolone response if absolute blast count is < 1000/cu.mm. 
2. Induction remission: The child is in remission if day 35 bone marrow during end of induction 
phase shows < 5% blast with Absolute neutrophil count (ANC) > 1000/cu.mm and platelet count > 1 
lakh/cu.mm without any evidence of extra medullary disease. 
3. Febrile neutropenia: Fever is defined as single oral temperature > or = 38.3 C (101F) single 
reading or > 38 C (100.4F) sustained over 1 hour. Neutropenia is defined as ANC < 500 cells/cu.mm 
or < 1000/cu.mm with expected fall below 500/cu.mm over the next 48 hours. We only included high 
febrile neutropenia requiring admission. 
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ALGORITHM:                       
 
                                                       Assessment for eligibility 
                                                                                                                                       
                                                              Retrieval of clinical records 
                                                                                    
            Collection of relevant data including anthropometric measures at various time points  
 
 Calculation of BMI and dividing the children into 3 nutrition groups 
 
 
                    Well-nourished                     Under nourished          Overweight/Obese 
                     Children(WN)                      children(UN)             children(OW/Ob) 
 
                            And assessment of the effect of nutritional status on various outcomes  
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Screening for metabolic syndrome in children who  completed treatment  
 
Assessment of eligibility 
 
Informed consent in overweight and obese children 
 
Measurement of waist circumference, blood pressure, and tanner’s staging was done. Blood samples for 
lipid levels, fasting glucose, insulin levels and HbA1c was collected. The presence of hypertension, 
hyperlipidaemia and impaired glucose tolerance was looked at. 
Statistical Methods 
Descriptive statistics for continuous variables was derived with mean and standard deviation  
or median with IQR (interquartile range)  and frequencies with percentages for categorical variables. Chi-
square test and Fischer’s test was used to compare proportions. The effect of various factors including 
nutrition on the outcome variables was analysed using Cox regression analysis.  
Sample Size Calculation 
 
A sample of size of 226(113 in well-nourished and 113 in the moderately & severely 
malnourished) children will be required to detect a 15 % difference in achieving remission between the 2 
groups at 80% power and 5% level of significance. We assume that the remission rate is 90 % in well-
nourished group and 75% in moderately and severely malnourished group after completion of induction 
phase. 
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RESULTS 
 
 
Two hundred and forty one children treated for Acute Lymphoblastic Leukaemia (ALL) were  
included in this analysis.   
Figure 1:  Male: Female ratio of the study population 
 
 
There were 157 boys and 84 girls. The male: female ratio in this group was 7:3  
Age at diagnosis 
 
The age at diagnosis of these children ranged from 11 months to 15 years; the mean age at 
diagnosis was 5.9 years (11months- 15 years). Children were divided into four groups based 
on their age; <1 year, 1-5 years, 6-10 years and >10years.   
55% of our study population were less than 5 years old at the time of diagnosis.  
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Table-1 Age at diagnosis 
N = 241 
 
 
Figure 2: Age at diagnosis  
 
 
 
Age No. of Children Percentage(%) 
 
<1yr 
 
2 
 
1 
 
1-5 yrs. 
 
 
130 
 
54 
 
6-10 yrs. 
 
78 
 
32 
 
11-15 yrs 
 
 
31 
 
13 
 
 
Total 
 
241 
 
100 
42 
 
 
Table 2: Age and gender distribution at diagnosis  
N = 241 
This table and graph show age and gender distribution of the study population. In all age 
groups the ratio of boy’s: girl’s was approximately 2:1.  
  
 
 
 
 
 
 
 
 
 
 
Figure 3: Age & Gender of the children at diagnosis 
 
Age Boys Girls 
 
<1yr 
 
2 
 
0 
 
1-5 yrs. 
 
 
83 
 
47 
 
6-10 yrs. 
 
51 
 
27 
 
11-15 yrs 
 
 
21 
 
10 
 
 
Total 
 
157 
 
84 
43 
 
 
Table 3: Type of  ALL 
N=241 
Most common type of ALL in this population was Pre B; followed by T cell ALL. 
 Bi-phenotype and Pro B constituted only < 5% .  
 
Figure 4 :Type of ALL 
 
 
 
Type of ALL No. of children Percentage (%) 
 
Pre B 
 
194 
 
81 
 
T cell 
 
 
34 
 
14 
 
Bi-phenotypic 
 
8 
 
3 
 
Pro B 
 
 
5 
 
2 
 
 
Total 
 
241 
 
100 
44 
 
 
Table 4: Type of ALL vs Gender  (N= 241) 
 
 
In this table and graph, we looked at type ALL and male: female ratio. In all groups 60-75% 
were boys.   
Figure 5 : Type of ALL vs Gender 
 
Type of ALL Boys Girls Total 
 
Pre B 
 
 
122(63%) 
 
72(37%) 
 
194 
 
T cell 
 
 
 
26(75%) 
 
8(25%) 
 
34 
 
Bi-phenotypic 
 
 
6(75%) 
 
2(25%) 
 
8 
 
Pro B 
 
 
 
3(60%) 
 
2(40%) 
 
5 
 
Total 
 
157 
 
84 
 
241 
45 
 
 
Table 5: Type of ALL vs Age  
 
 N = 241 
  
 
In all age groups, except <1year, Pre B ALL was the predominant type of leukaemia.   
 
 
 
 
 
 
 
 
 
Age Pre B T cell ALL Bi-phenotypic Pro B Total  
 
<1yr 
 
 
1(50%) 
 
0 
 
0 
 
 1(50%) 
 
2 
 
1-5 yrs. 
 
 
111(86%) 
 
9(7%) 
 
7(5%) 
 
3(2%) 
 
130 
 
6-10 yrs. 
 
 
57(73%) 
 
20(26%) 
 
0 
 
1(1%) 
 
78 
 
11-15 yrs 
 
 
25(81%) 
 
5(16%) 
 
 
1(3%) 
 
0 
 
31 
 
Total 
 
194 
 
34 
 
8 
 
5 
 
241 
46 
 
Table 6: WBC count vs type of ALL  
 
     
 
When children were divided based on the WBC count at diagnosis, majority ( 78%) had 
counts ranging from 20-100 thousand. 6% had <20,000/c.mm and 16% had >1Lakh WBC at 
diagnosis.  
 
11/14 (78%) children with WBC<20,000 had Pre B ALL. None of the T ALL had low WBC 
count at presentation.. Among those with high WBC at diagnosis, 55% had T ALL. 
 
Among all cases of T ALL, 57% had >100,000 WBC at diagnosis 
 WBC <20,000 20,000 – 
1,00,000 
>100,000 Total 
 
Pre B 
 
 
11 
 
165 
 
15 
 
191 
 
T cell 
 
 
 
0 
 
16 
 
21 
 
37 
 
Bi-phenotypic 
 
 
2 
 
6 
 
0 
 
8 
 
Pro B 
 
 
 
1 
 
2 
 
2 
 
/5 
 
Total 
 
14(6%) 
        
       189(78%) 
 
38(16%) 
 
241 
47 
 
 
CNS  and Testicular Disease: 
 
All children had a diagnostic lumbar puncture done at first admission. Those who had >5 
blasts in the CSF or any parenchymal disease or cranial nerve palsies were considered to have 
CNS involvement.  Children with enlarged testes at diagnosis were diagnosed to have 
testicular disease.   
 
38/241 (16%) had CNS disease and 3/157(2%) boys had testicular disease in our study 
population.  
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Table 7: CNS disease vs Gender 
N = 241. 
 
 P = 0.09 
17% of boys and 13% of girls had CNS disease. There was no significant difference in the 
incidence of CNS disease between boys and girls.  
 
Figure 6: CNS Disease vs Gender 
 
 
Gender CNS disease  
Present 
CNS disease  
Absent 
 
Total 
 
Boys 
 
 
27 
(17%) 
 
130 
(83%) 
 
157 
 
Girls 
 
 
 
11 
(13%) 
 
73 
(87%) 
 
84 
 
Total 
 
 
38 
 
203 
 
241 
49 
 
Table 8: CNS disease vs type of ALL 
N =241 
 
 
Chi Sq=7.03 and p=0.008 
Incidence of CNS disease was higher in T call ALL ( 38%) compared to Pre B ALL (12%).  
Higher incidence of CNS disease in biphenotypic ALL and Pro-B ALL is because of smaller  
number of cases in these groups.  
 
 
 
 
 
 
 
 
 
Type of ALL CNS disease 
Present 
CNS disease 
absent 
Total 
 
Pre B 
 
 
24(12%) 
 
170 
 
194 
 
T cell 
 
 
 
9(26%) 
 
25 
 
34 
 
Bi-phenotypic 
 
 
3(38%) 
 
5 
 
8 
 
Pro B 
 
 
 
2(40%) 
 
3 
 
 
5 
 
Total 
 
38 
 
203 
 
241 
50 
 
Table 9: Age of children with CNS disease  
N= 38  
 
 
 
 
 
 
 
 
 
 
 
There was no difference in the incidence of CNS disease in the three age groups.  
 
Table 10: WBC at presentation vs CNS disease 
 
Chi sq = 10.79       p=0.005 
Age group CNS disease 
Present 
 
<1yr 
 
 
0 
 
1-5 yrs. 
 
 
23/130 (18%) 
 
6-10 yrs. 
 
 
10/78 (13%) 
 
11-15 yrs 
 
 
5/31 (16%) 
 
Total 
 
38 
 CNS disease 
Present 
CNS disease 
absent 
Total 
 
WBC < 20,000 
 
 
14 
(93%) 
 
1 
 
15 
 
WBC 20,000 - 1,00,000 
 
 
 
12 
(6%) 
 
175 
 
187 
 
WBC >100,000 
 
 
12 
(30%) 
 
27 
 
39 
 
Total 
 
38 
 
203 
 
241 
51 
 
Table 11: WBC count vs CNS disease vs type of ALL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When we compared WBC count and type of leukaemia in children with CNS disease, it was 
found that in children with WBC<100,000/c.mm. Pre B ALL was the most common type of 
leukaemia. In the high WBC group, T cell ALL   accounted for 75% of cases.   
  
 
 
 
 
 
 
 CNS disease 
Present 
Type of ALL 
 
WBC < 20,000 
 
 
14 
 
 
 
Pre B – 12 
 
Bi-phenotypic - 2 
 
WBC 20,000 - 1,00,000 
 
 
 
12 
 
 
Pre B – 11 
 
Pro B  - 1 
 
 
WBC >100,000 
 
 
12 
 
 
Pre B – 1 
 
T cell -  9 
 
Bi-phenotypic – 1 
 
Pro B  - 1  
 
Total 
 
38 
 
52 
 
Table 12: Cytogenetic analysis 
  N=158 
 
Cytogenetic profile was available for 158 children in this group. Only numerical 
abnormalities are depicted here. 
 
 
 
 
Overall, 40% of children had normal karyotype and 55% had hyperdiploidy. Hypodiploidy 
was seen only in 5% of cases. Further break up of type of ALL showed 57% of Pre B ALL 
cases had hyperdiploidy.  
 
 
 
 Normal Hyper-diploidy Hypo-diploidy Total 
 
Pre B 
 
 
49 
(38%) 
 
74 
(57%) 
 
7 
(5%) 
 
130 
 
T cell 
 
 
13 
(59%) 
 
8 
(36%) 
 
1 
(5%) 
 
22 
 
Bi-phenotypic 
 
0 
 
2 
 
 
0 
 
2 
 
Pro B 
 
 
1 
 
 
3 
 
 
0 
 
4 
 
Total 
 
63(40%) 
 
87(55%) 
 
8(5%) 
 
      158 
53 
 
 
Table 13: Risk stratification 
 
Children were stratified into three risk groups based on various parameters at diagnosis as 
well as response to treatment. 25% of children had high risk disease.  
 
N = 241. 
 Frequency Percentage 
 
Standard risk 
 
80 
 
33% 
 
Intermediate risk 
 
101 
 
42% 
 
High risk 
 
60 
 
25% 
 
Total 
 
241 
 
100% 
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Table 14: Risk Stratification  vs Type of ALL 
It was interesting to note that only children with Pre B ALL were in the standard risk group. 
65% of T ALL cases had high risk disease. 
 
 
N=241. 
 
 
 
 
 
 
 Standard 
Risk 
Intermediate 
Risk 
High risk Total 
 
Pre B 
 
 
80 
(41%) 
 
82 
(42%) 
 
32 
(17%) 
 
194 
 
T cell 
 
 
0 
 
12 
(35%) 
 
22 
(65%) 
 
34 
 
Bi-phenotypic 
 
 
0 
 
6 
(75%) 
 
2 
(25%) 
 
8 
 
Pro B 
 
 
0 
 
1 
(20%) 
 
4 
(80%) 
 
5 
 
Total 
 
80 
 
 
101 
 
 
60 
 
 
241 
55 
 
 
Nutritional  Status of Children  
 
Nutritional Status of Children at diagnosis (N= 227): 
Of the 241 children included in the study, 14 children were < 2 years of age and 
therefore had to be excluded from the BMI analysis at diagnosis. Thus data of 227 children 
were analysed for nutritional status.  BMI was calculated from the recorded height and 
weight. 
Children were stratified as under-nourished (UN), well-nourished (WN) ,over-weight (OW) 
and obese(Ob) using CDC BMI centile chart.  
Flow chart                           
 
                                                                    Total number of deaths: 34 
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Table 15: Nutritional status  at diagnosis (N=227)   
 
 
Figure 7: Nutritional status  at diagnosis 
 
 
The table and pie chart show nutritional status of children at diagnosis, based on BMI. 47% 
of children were well nourished and   44% were under nourished. 9% were 
Obese/overweight.  
 
 No. of children Percentage (%) 
 
Under Nourished 
 
101 
 
44 
 
Well Nourished 
 
 
106 
 
47 
 
Overweight / Obese 
 
20 
 
9 
 
Total 
 
227 
 
100% 
57 
 
Table 16:  Nutritional Status  at diagnosis vs Gender:  
 
 
 
There was no difference in the nutritional status between boys and girls in our study 
population.  
 
Figure 8: Nutritional status at diagnosis vs Gender 
 
 
 Boys Girls Total 
 
Under Nourished 
65 
(43%) 
36 
(46%) 
101 
 
Well Nourished 
 
73 
(48%) 
33 
(44%) 
106 
 
Overweight / Obese 
14 
(9) 
6 
(10%) 
20 
               Total 152 75 227 
58 
 
 
Table 17: Nutritional status at diagnosis vs Age and Gender of the children 
N = 227 
 
*In this group 14 children were excluded from analysis as they were less than 2 years of age. 
When we compared nutritional status with age and gender, the distribution of cases were 
similar in all groups.  
 
 
 
 
Gender 
 
Age Group 
 
Under Nourished 
 
Well Nourished 
 
Over Weight/ 
Obese 
 
Boys 
(150) 
 
1- 5 yrs* 
(78) 
 
30 
(39%) 
 
40 
(51%) 
 
8 
(10%) 
  
5-10 yrs 
(51) 
 
24 
(47%) 
 
23 
(45%) 
 
4 
(8%) 
  
10-15 yrs 
(21) 
 
12 
(57%) 
 
8 
(38%) 
 
1 
(5%) 
 
Total 
 
150 
 
66(44%) 
 
71(48%) 
 
 
13(8%) 
 
Girls 
(77) 
 
1-5 yrs 
(40) 
 
16 
(40%) 
 
20 
(50%) 
 
4 
(10%) 
  
5-10 yrs 
(27) 
 
17 
(63%) 
 
10 
(37%) 
 
0 
  
10 -15yrs 
(10) 
 
2 
(20%) 
 
6 
(60%) 
 
2 
(20%) 
 
Total 
 
77 
 
35(45%) 
 
36(46%) 
 
6(8%) 
59 
 
Table 18: Nutritional status at diagnosis vs type of ALL: 
N = 227 
 
There was no difference in the distribution of nutritional groups between different types of 
leukaemia.  
 
 
 
 
 
 
 
 
 
 Under 
Nourished 
Well Nourished Over 
Weight/Obese 
Total 
 
Pre B 
 
 
77 
(42%) 
 
90 
(49%) 
 
16 
(9%) 
 
183 
 
T cell 
 
 
19 
(58%) 
 
11 
(36%) 
 
3 
(6%) 
 
33 
 
Bi-phenotypic 
 
 
3 
(50%) 
 
2 
(33%) 
 
1 
(17%) 
 
6 
 
Pro B 
 
 
2 
(40%) 
 
3 
(60%) 
 
0 
 
5 
 
Total 
 
101 
 
 
106 
 
 
20 
 
 
227 
60 
 
Table 19: Nutritional status  at diagnosis vs Risk group 
N=227 
 
The distribution of cases in the three risk groups were similar in terms of their nutritional  
status as shown in the table and  bar diagram  
 
Figure 9: Nutritional status  at diagnosis vs Risk group 
 
 
 Standard 
Risk 
Intermediate 
Risk 
High risk Total 
 
Under Nourished 
 
39 
(39%) 
 
37 
(36%) 
 
25 
(25%) 
 
101 
 
Well Nourished 
 
 
32 
(30%) 
 
49 
(47%) 
 
25 
(37%) 
 
106 
 
Over weight/ Obese 
 
 
7 
(37%) 
 
9 
(42%) 
 
4 
(21%) 
 
20 
 
Total 
 
78 
 
 
95 
 
 
54 
 
 
227 
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Longitudinal assessment of nutritional status from diagnosis 
through treatment and post treatment follow up period. 
 
Of the 227 children included in this study, 34 children died due to various reasons during 
treatment. 195 completed treatment. In this part of the study, evaluated their nutritional status 
during and after completion of therapy, impact of nutritional status on response to treatment 
and complications 
FLOW CHART 
 
 
                                 
                                                             Total number of deaths -34 
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Table 20: Nutritional status of children from diagnosis till end of treatment 
 
N = 195 
  
  
Diagnosis 
 
DI 
 
M1 
 
End of Rx 
 
Under Nourished 
 
85 
(44%) 
 
57 
(29%) 
 
37 
(19%) 
 
25 
(13%) 
 
Well Nourished 
 
96 
(49%) 
 
114 
(59%) 
 
125 
(64%) 
 
113 
(58%) 
 
Over weight/ Obese 
 
14 
(7%) 
 
24 
(12%) 
 
33 
(17%) 
 
57 
(29%) 
 
P = < 0.05 
      DI-delayed intensification, 
     M1- beginning of maintenance 
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Figure 10: Change in Nutritional status of children from diagnosis till end of treatment 
 
 
 
 
              The above table depicts the changes in BMI centile along the course of treatment. 
Under nourished children tend to decrease in number along the course. 44% were 
undernourished at diagnosis, 29% during DI, 19 % during beginning of maintenance and only 
13% remained in the same group at the end of treatment. Children who were well nourished 
either remained well- nourished or move to the overweight/obese group. Only 7% of the 
children were over-weight/obese at diagnosis but by the end of treatment 29% moved to this 
group.  
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                Analysing the number of children in relation to nutritional status from diagnosis to 
end of treatment, 85 children were undernourished at diagnosis-23 remained the same,51 
became well- nourished and 11 became  overweight/obese. Among the 96 children who were 
well nourished at diagnosis, 59 remained the same, 2 became undernourished and 35 moved 
to the overweight/obese group. Among the 14 overweight/obese children at diagnosis, 11 
remained the same and 3 became well nourished. 
We further analysed the data to see at which point children moved from a lower to a higher 
nutritional status for example from under-nourished to well- nourished and well- nourished to 
overweight/obese group. 
Point 1 –from beginning of induction to beginning of delayed intensification 
 85(44%) children were undernourished at diagnosis, 32(38%) moved to the well-nourished 
group and 2(2%) to the overweight/obese group. 
96 (49%) children were well-nourished at diagnosis out of which 9(9%) children moved to 
the overweight/obese group while 70(73%) remained in the same group. 
Point 2- from beginning of induction to beginning of maintenance 
85(44%) children were undernourished at diagnosis, 44(52%) moved to the well-nourished 
group and 5(6%) to the overweight/obese group. 
96 (49%) children were well-nourished at diagnosis out of which 17(18%) children moved to 
the overweight/obese group while 51(53%) remained in the same group. 
Hence this shows that it is more likely that children tend to move to higher nutrition status by 
the beginning of maintenance. 
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Table 21: Nutritional Groups at diagnosis vs  end of treatment 
 
  
Diagnosis 
 
End of Treatment 
 
Under Nourished 
 
85(44%) 
 
25(13%) 
 
Well  Nourished 
 
96(49%) 
 
113(58%) 
 
Over weight / Obese 
 
14(7%) 
 
57(29%) 
 
Total 
 
195 
 
195 
N = 195. 
Chi. Sq. = 48.4 
p = <0.05 
23 children in the UN group remained so at the end of treatment and 2 children in the WN 
group moved into the UN group at the end of the treatment. The vast majority of children 
(87%) remained well- nourished or improved their , nutrition status during treatment.   
Figure 11: At diagnosis vs  end of treatment 
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Table 22: Nutritional Groups at end of treatment  vs  at  1yr follow up  
Out of 195, 185 children came for follow up at 1 year. 
N = 185. 
p = <0.05 
The above table depicts the change in weight from end of treatment to 1 year follow up.Most 
of the children from the well nourished group remained in the same group. The percentage of 
children who became overweight/obese has increased. 
  
 
 
 
 
At 1
st
 year  
follow up 
 
 
 
At end of  
Treatment 
 
Under 
Nourished 
 
 
Well Nourished 
 
 
Over Weight / 
Obese 
 
Total 
 
 
Under Nourished 
25 
 
16 
(64%) 
 
8 
(32%) 
 
 
1 
(4%) 
 
25 
 
Well 
Nourished 
107 
 
7 
(7%) 
 
89 
(83%) 
 
11 
(10%) 
 
107 
 
 
Over Weight 
/  Obese 
53 
 
2 
(4%) 
 
9 
(17%) 
 
42 
(79%) 
 
53 
Total=185    185 
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Table 23: Nutritional Groups at end of treatment  vs  at  2yr follow up 
 
 
N = 145. 
Chi. Sq. = 114.4 
p = <0.05 
The above table shows the similar change in weight from end of treatment to 2 year follow 
up. By the end of 2
nd
 year, there were no undernourished children. All had moved to the well 
-nourished group or the overweight/obese group.  
 
 
At 2
nd
 year 
 follow up 
 
 
 
At end of  
Treatment 
 
Under Nourished 
 
 
Well Nourished 
 
 
Over Weight / Obese 
 
Total 
 
 
Under Nourished 
19 
 
13 
(68%) 
 
6 
(32%) 
 
 
0 
 
19 
 
Well 
Nourished 
84 
 
8 
(10%) 
 
60 
(71%) 
 
16 
(19%) 
 
84 
 
 
Over Weight 
/  Obese 
42 
 
0 
 
6 
(14%) 
 
36 
(86%) 
 
42 
Total= 145    145 
68 
 
Table 24: Nutritional Groups at end of treatment  vs  at 3yr follow up 
 
At 3 year  
follow up 
 
 
At end of 
treatment 
 
Under 
Nourished 
 
 
Well Nourished 
 
 
Over Weight / 
Obese 
 
Total 
 
Under Nourished 
10 
 
5 
(50%) 
 
5 
(50%) 
 
 
0 
 
10 
 
Well 
Nourished 
48 
 
2 
(4%) 
 
32 
(67%) 
 
14 
(29 %) 
 
48 
 
 
Over Weight 
/  Obese 
23 
 
0 
 
2 
(14%) 
 
21 
(86%) 
 
23 
Total =81    81 
 
N = 81. 
Chi. Sq. = 62.30 
p = <0.05 
The Table shows that none of the children were undernourished at 3 year follow up. By the 
end of the 3
rd
 year 86% of the children were in the overweight/obese group. 
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Table 25: Nutritional Groups at end of treatment  vs  at  5yr follow up 
 
 
N = 34. 
Chi. Sq. = 31.56 
p = <0.05 
 
 
 
 
 
 
At 5 year 
 follow up 
 
 
 
At end of  
Treatment 
 
Under Nourished 
 
 
Well Nourished 
 
 
Over Weight / Obese 
 
Total 
 
Under Nourished 
6 
 
4 
(66.7%) 
 
2 
(33.3%) 
 
 
0 
 
6 
 
Well 
Nourished 
17 
 
1 
(5.9%) 
 
13 
(76.5%) 
 
3 
(17.66 %) 
 
17 
 
Over weight 
/  Obese 
11 
 
0 
 
2 
(18.2%) 
 
9 
(81.8%) 
 
11 
Total – 34    34 
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Table 26: Nutritional status of children from diagnosis till last follow up  
 
 
 
Nutritional  
Status 
 
 
At 
diagnosis 
 
End of 
treatment 
 
First yr.  
follow up 
 
Second yr. 
 follow up 
 
Third yr. 
follow up 
 
Fifth yr. 
follow up 
 
Under 
Nourished 
 
 
        85 
      (44%) 
 
25 
(13%) 
 
21 
(11%) 
 
21 
(14%) 
 
7 
(9%) 
 
5 
(15%) 
 
Well 
Nourished 
 
 
96 
      (49%) 
 
113 
(58%) 
 
106 
(47%) 
 
72 
(50%) 
 
39 
(47%) 
 
17 
(50%) 
 
Over weight 
/  Obese 
 
 
14 
(7%) 
 
57 
(29%) 
 
54 
(29%) 
 
52 
(35%) 
 
35 
(43%) 
 
12 
(35%) 
 
Total  
 
195 
 
195 
 
185 
 
145 
 
81 
 
34 
   
The above Table shows close to 70% of the children in the UN group, gained weight during 
treatment such that the percentage of children in the UN group steadily decreased (p < 0.05 
between diagnosis and end of treatment). Thereafter this group remained the same up to 2 
years post-treatment and once again showed some weight gain.  
The nutrition in the WN group remained rather steady from diagnosis till the final follow-up 
except for some weight gain during the treatment phase. In the OW/Ob group, there was 
significant (p < 0.05) increase in weight such that the percentage of children increased 4 fold 
in this group by the end of treatment. By 5 years post-treatment the percentage of children in 
this category stabilised to about 5 fold the number at diagnosis. 
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Figure 12: Nutritional status of children from diagnosis till 5 years of  follow up 
 
 
 
 
 
Figure and Table show a gradual increase in weight on follow up in children who completed 
treatment for ALL. Most of the children are either well nourished or overweight/obese as 
early as the 1
st
 and 2
nd
 year of follow up. 
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Impact of Nutritional Status on response to treatment in children 
with ALL 
Table 27: Nutritional Groups vs Early response (Early response to Rx. – Day 8 blast count) 
N-227 
p = 0.955 chi. sq.= 0.09 
GPR – Good prednisolone response -  Day 8 blast count < 1000 
PPR- poor prednisolone response    - day 8 blast count > 1000 
Of the 20 children who had PPR, 14 were high risk, 5 were intermediate risk and  
1 belonged to the standard risk group. 
Figure 13: Nutritional Groups vs early response   
 
Predominantly children in the undernourished group had PPR .  
 
 
 
GPR 
 
PPR 
 
Total 
 
Under Nourished 
 
 
88 
 
 
13 
(13%) 
 
101 
 
Well Nourished 
 
 
101 
 
 
6 
(6%) 
 
107 
 
Over Nourished /Obese 
 
 
18 
 
 
1 
(5%) 
 
19 
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Table 28: Nutritional status at diagnosis vs Bone marrow response to treatment – Day 14 
blast percentage 
N = 227   
 
 
 
Remission 
 
Residual Disease 
 
Total 
Under Nourished 
 
95 6  
101 
Well Nourished 
 
107 0  
107 
Over Nourished 
/Obese 
 
19 0  
19 
 
P = 0.215 
 
Figure 14: Nutritional status at diagnosis vs Bone marrow response 
   
 
 
The above figure shows that 6 children in the under nourished group had residual disease on 
day 14 bone marrow.Of the 6 children,5 belonged to the high risk group and 1 child had 
intermediate risk. 
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Table 29: BMI  vs Bone Marrow Remission(Bone marrow remission at day 35 (end of 
induction) 
 BM 
Remission 
Not in  
Remission 
 
Total 
Under 
Nourished 
 
 
89 
 
4 
(4%) 
 
93 
Well 
Nourished 
 
97 
 
3 
(3%) 
 
100 
Over Nourished 
/  Obese 
 
13 
 
2 
(13%) 
 
15 
Total 199 9* 208 
(p = 0.186)  
*Totally there were 10 children with residual disease, only 9 of them were analysed, as one of 
them was < 2 years of age at diagnosis. 
Of the 10 children, 7 were from the high risk group, and 3 from intermediate group 
Figure 15: BMI vs Bone Marrow Remission(end of induction) 
 
There was no significant difference in the end of induction remission in relation to the 
nutritional groups. 
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Table 30: Nutritional status at diagnosis vs Febrile neutropenia episodes during treatment 
This data was available for 215 children. 
 
  
0 
 
1 
 
 
2 
 
 
3 
 
4 
 
5 
 
6 
 
7 
 
Total 
Under Nourished 
 
 
17 
 
25 
 
20 
 
18 
 
10 
 
5 
 
1 
 
0 
 
96 
Well 
Nourished 
 
19 
 
30 
 
24 
 
16 
 
11 
 
0 
 
1 
 
0 
 
101 
Over weight 
/  Obese 
 
3 
 
6 
 
5 
 
1 
 
2 
 
0 
 
0 
 
1 
 
18 
Total 39 61 49 35 23 5 2 1 215 
(p = 0.135)  
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Table 31: Nutritional status at diagnosis vs Febrile neutropenia episodes during treatment 
N-215  
Clubbing the number of febrile neutropenia episodes into 0-3 episodes and > 3 episodes 
    0-3 episodes      4-7 episodes Total 
Under nourished               80               16 96 
Well nourished                89               12 101 
Overweight/obese                15                3  18 
 
Table 31 showed no significant difference found in the number of episodes of febrile 
neutropenia in relation to the nutritional status of children at diagnosis. 
4 children who had no febrile neutropenia episodes relapsed. 
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Table 32: Nutritional status at diagnosis vs Relapse and time of relapse 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15/ 195 children relapsed- 4 during treatment and 11 after completion of treatment.  
There was no significant difference in the number of children relapsed between different  
nutritional groups.  
 
 
 
 
 
 
 
 
  
Relapse  
during treatment 
 
 
Relapse  
after 
treatment 
 
 
Under Nourished 
(85) 
 
2 
 
4 
 
Well Nourished 
(95) 
 
2 
 
6 
 
Over weight/ Obese 
(14) 
 
 
0 
 
1 
 
Total (195)
 
 
4 
 
11 
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Table 33: Nutritional status( at diagnosis) of  children who died during treatment  
 
34 children died during treatment. For the purpose of analysis we divided them into two 
groups; well nourished and not-well nourished. The not –well nourished group included both 
under nourished and overweight/obese.  
 
  
Dead 
 
Alive 
 
Total 
Well 
Nourished 
 
11 
(10%) 
 
96 
(90%) 
 
107 
 
Not - Well 
Nourished 
 
21 
(18%) 
 
99 
(82%) 
 
120 
 
Total 
 
32* 
 
195 
 
227 
 
 
 
(p = 0.09) 
*2 patients were excluded in the above table as they were less than 2 years of age at diagnosis 
and hence BMI could not be analysed. 
10% of well nourished and 18% of not-well nourished died.  
There was no statistically significant difference between the groups, probably because the 
numbers were small and also could be that there are many other factors contributing to their 
death.  
 
 
 
78 
 
Table 34: Nutritional status at diagnosis  vs  Phase of treatment  at death 
 
  
Ind 
 
Con. 
 
 
DI 1 
1 
 
DI 2 
1 
 
DI 2 
2 
 
IM 1 
 
IM 2 
 
Maint. 
 
Total 
Under Nourished 
 
 
8 
 
1 
 
3 
 
0 
 
1 
 
0 
 
1 
 
2 
 
16 
Well 
Nourished 
 
6 
 
0 
 
1 
 
2 
 
0 
 
1 
 
0 
 
1 
 
11 
Over weight 
/  Obese 
 
5 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
5 
 
Total 
 
19 
 
1 
 
4 
 
2 
 
1 
 
1 
 
1 
 
3 
 
32 
(p = 0.585)  
 
Ind - Induction 
Con - Consolidation 
DI -Delayed Intensification 
IM - Interim Maintenance 
M - Maintenance 
 
*2 patients were excluded in the above table as they were less than 2 years of age at diagnosis 
and hence BMI could not be analysed 
 
The above table shows the phase of treatment when these children died.  19/34 (59%) 
children died during induction phase of treatment. There didn’t seem to be any correlation 
between nutritional status and mortality.  
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Table 35: Risk stratification at diagnosis vs death 
 
  
Dead 
 
Alive 
 
Total 
 
Standard risk 
  
 
          10 
(30%) 
 
70 
 
80 
 
Intermediate risk 
 
12 
(35%) 
 
83 
 
95 
 
High risk 
 
 
12 
(35%) 
 
40 
 
52 
 
Total 
 
34 
 
195 
 
227 
(p = 0.084)  
 
Analysis of the children who died, there was no statistical significance in relation to risk 
strategy. 
 
Table 36: Risk Stratification at  diagnosis  vs Phase of chemotherapy at  death 
 
 
Risk Stratification 
 
Ind 
 
Con. 
 
 
DI 1 
1 
 
DI 2 
1 
 
DI 2 
2 
 
IM 1 
 
IM 2 
 
Maint. 
 
Total 
Standard 
 
 
6 
 
0 
 
1 
 
1 
 
0 
 
0 
 
0 
 
2 
 
10 
Intermediate  
6 
 
0 
 
3 
 
1 
 
0 
 
1 
 
0 
 
1 
 
12 
High  
6 
 
1 
 
1 
 
2 
 
0 
 
1 
 
0 
 
1 
 
12 
 
Total 
 
18 
 
1 
 
5 
 
4 
 
0 
 
2 
 
0 
 
4 
 
34 
 
p = 0.857 
Cause of death: All the children died due to severe sepsis with febrile neutropenia. Most of 
them died during the induction phase.   
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Screening for metabolic syndrome  in children who had 
completed treatment and reviewed during the study period 
 
Of the 195 children who successfully completed treatment 114 children came for review to 
the outpatient clinic during the study period and were included in this analysis. Their 
nutritional status was assessed and those who were overweight/obese were screened for   
features of metabolic syndrome.  
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
No. of children who completed treatment = 195 
No. of children followed up in OPD = 114. 
( Nutritional status at diagnosis was assessed only for 112 children as 2 of the 114 
children were  < 2 years of age) 
 
 
No. of children found to be overweight / obese children = 30 
( Nutritional status at diagnosis was assessed only for 28 children as 2 of the 30 were 
< 2 years of age) 
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Total children followed up in OPD -114, 78 boys and 36 girls. 
 
Figure 16 : Gender distribution at follow up: 
 
 
 
 
 
 
The mean age at diagnosis was 5.8 years (range 11months to 14.3years) 
 
 
 
 
 
 
82 
 
\Table 37: Age distribution at diagnosis  
 
Age No. of children 
< 2 year 4(3%) 
2-5 years 61(54%) 
6-10 years 35(31%) 
11-15 years 14(12%) 
Total -114 
 
Figure 17: Age distribution at diagnosis 
 
 
 
 
The above table and graph shows that most of the children belonged to 2 -5 years age group. 
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Table 38 : Age and Gender distribution at follow up: 
 Boys Girls Total 
< 1 year 2 0 2 
1-5 years 45 18 63 
6-10 years 20 15 35 
11-15 years 11 3 14 
Total 78 36 114 
 
The mean follow up of these children after completion of treatment was 2.4 years.( range 3 
months to 9 years) 
 
Table 39: Nutritional status at diagnosis vs end of treatment  vs follow up.  
N=114 
 
 At diagnosis End of  treatment On follow up 
Under nourished 55 
( 48%) 
19 
(17%) 
5** 
(4%) 
Well nourished  51 
( 45%) 
70 
( 61%) 
81 
( 71 %) 
Overweight/obese 6 
( 5 %) 
25/27 
(22%) 
28/30 
(25%) 
Total  112* 114 114 
P < 0.005 
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* 2 children were < 2 years of age at diagnosis, hence their BMI centile was not calculated. 
** 5 children in the under nourished group at follow up were undernourished at diagnosis 
also. 
Figure 18: Nutritional status at diagnosis vs end of treatment  vs follow up.  
N=114 
 
 
The above figure depicts the change in weight over the course of treatment. At diagnosis 
,48% were undernourished, by the end of treatment only 17% remained in this group and at 
follow up  only 4% remained in this group. The percentage of children in the well- nourished 
group steadily increased. Although the percentage of children in the OW/Ob group 
significantly increased during treatment, between the end of treatment and follow-up, there 
was no significant increase in the number of children in this group. Thus most of the 
increments in BMI occurred during treatment (p value <0.005) and there was no significant 
change from completion of treatment to follow up.  
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Analysis of overweight/obese patients at follow up 
 
Thirty children were found to be overweight/obese among those who were followed up 
during the study period. There were 22 boys and 8 girls. The prevalence of obesity in this 
group was 26 %.The mean age at follow up was 10.3 years (range 6 years to 15 years). 
The age distribution is as follows:  
Table 40: Age distribution of overweight/obese children                  
N=30 
Age No. of children 
5-10 years 14(47%) 
10-15 years 16(53%) 
 
Mean BMI was 24.1kg/m
2 
(range 19.2 to 32.8) 
 
Table 41: Age at follow up, Gender and BMI 
 
Age Boys Mean BMI Girls Mean  BMI 
 
6-10 years 
 
           10 
 
23.7 
 
5 
 
21.9 
 
11-15 years 
 
12 
 
25 
 
3 
 
24.7 
 
Total 
 
22 
  
8 
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Table 42: Linear growth of the children at follow up 
 
Total no. of Children Current height 
centile  
corresponding to 
target  height  
Current 
height centile 
>Target 
height 
Current height 
centile < Target 
height 
 
30 
 
 
6(20%) 
 
19(63%) 
 
5(17%) 
 
The above table shows that while 20% of children had height corresponding to their target 
height, 17% had height centile below the target height. Interestingly 63% children had height 
above their target range.  
 The mean duration between completion of treatment and follow up was 2.1 years.(range  3 
months to 9 years) 
Six children (20%) were in puberty and 24 children (80%) were pre-pubertal as shown below. 
No one had precocious puberty. 
 
Table 43 : Age vs Tanner stage 
 
 Tanner stage 1 
Pre pubertal 
Tanner stage ≥ 2 
 
5-10yrs 
 
14(47%) 
 
0 
 
10 -15 yrs 
 
10(33%) 
 
6(20%) 
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Table 44: Tanner stage vs gender  
 
 Tanner stage 1 Tanner stage ≥ 2 
 
Boys(22) 
 
            19 
 
         3 
 
Girls(8) 
 
            5  
 
         3 
 
 
Comparing their nutritional status at different time points of ALL 
treatment. 
 
Table 45: BMI - at diagnosis vs during beginning  of maintenance  (M1) vs end of treatment. 
N=30 
 Diagnosis DI M1 End of Rx. At follow 
up 
Under Nourished 6 0 0 0 0 
Well Nourished 16 17 8 2 0 
Overweight/obese 6 11 22 28 30 
Total 28* 28* 30 30 30 
 
Fisher’s exact   <0.05 
*2 patients were less than 2 years of age at diagnosis. 
DI –Delayed intensification 
M1 – Beginning of maintenance 
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Figure 19: BMI  - at diagnosis till end of treatment. 
 
 
 
 
The above graph shows the change in weight of the 30 children during the course of 
treatment and follow-up.  
6 children who were undernourished at diagnosis had caught up in weight by the beginning of 
delayed intensification phase itself and beyond this phase of treatment none were 
undernourished. . 
 16 children who were well nourished at diagnosis became overweight/obese by the end of 
treatment and remained so at follow-up. The number of children in the OW/Ob group steadily 
increased from 6 at diagnosis to 28 at the end of treatment. Only 2 children subsequently 
moved into this group during follow-up. The increase in BMI was statistically significant (p < 
0.05).   
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Figure 20: Cumulative graph showing increase in obesity. 
 
Among those who were overweight/obese at follow up, significant weight gain occurred 
during the induction phase of treatment such that the numbers doubled by the end of 
induction phase. By the beginning of maintenance phase close to 80% were obese. 
Figure  21: BMI  - From diagnosis to final follow up. 
 
The above graph and tables shows that BMI centile is on the increasing trend from diagnosis 
to the end of treatment and follow up. 
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Table 46: Progression of weight of the 6 undernourished children who became obese: 
  Diagnosis D.I. M 1   End of 
Rx. 
Follow 
Up 
1
st
 child UN WN OW OW OW 
2
nd
 child UN WN OW Ob OW 
3
rd
 child           UN WN Ob Ob Ob 
4
th
 child UN OW OW OW OW 
5th child UN WN OW OW     OW 
6
th
 child UN WN WN OW OW 
 
UN – Under Nourished                               DI- Delayed intensification 
WN – Well Nourished                                M1- Beginning of maintenance 
OW– Over weight 
Ob - Obese 
Five out of six children were undernourished at diagnosis moved into well- nourished group 
and one child became overweight by the end of induction phase. By the end of delayed 
intensification phase five of them had become overweight/obese and remained so till follow 
up. 
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Number of children who have received Cranial RT: 
Table 47: children who received RT 
 
Cranial irradiation Frequency Percentage(%) 
Given 6 20 
Not Given 24 80 
Total 30 100 
 
Only 6(20%) children received cranial irradiation, while 80% did not receive cranial 
irradiation. Children  with definite CNS disease received 18 GY and those with traumatic 
CSF received 12 Gy . 
Children who received Cranial RT were analysed according to their nutritional status from 
diagnosis to the end of treatment which is shown below. 
 
Table 48: Nutritional status at Diagnosis vs Cranial RT 
 
 Cranial RT  
Given 
Cranial RT 
Not Given 
Total 
Under Nourished 2 
(33%) 
4 6 
Well Nourished 3 
(18%) 
15 18 
Over weight/ Obese 1 
(17%) 
5 
 
6 
Total 6 24 30 
Fisher’s exact = 0.311    RT- radiotherapy 
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Table 49:  Nutritional status  at Maintenance vs Cranial RT 
 
 Cranial RT  
Given 
Cranial RT 
Not Given 
Total 
Under Nourished 0 
 
0 0 
Well Nourished 2 
(25%) 
6 
(75%) 
8 
Over weight / Obese 4 
(18%) 
18 
(82%) 
22 
Total 6 24 30 
Fisher’s exact = 0.217 
 
Table 50: Nutritional status  at End of treatment and Follow up vs Cranial  RT 
 
 Cranial RT  
Given 
Cranial RT 
Not Given 
Total 
Under Nourished 0 
 
0 0 
Well Nourished 0 
 
2 2 
Over weight / Obese 6 
(22%) 
22 
(78%) 
28 
Total 6 24 30 
 
Fisher’s exact = 0.99 
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Figure 22: Nutritional status of children (who received Cranial RT ) -  at diagnosis vs 
beginning of maintenance  vs end of treatment 
 
 
Analysis of the nutritional status of the children who received cranial Radiotherapy depicts an 
upward trend towards the overweight/ obese category but was not statistically significant 
(p=0.99) 
 
Table 51: Relapse  
 
Relapse Frequency Percentage(%) 
No 29 97 
Yes 1 3 
Total 30 100 
 
There was only one patient (3.3%) who had CNS relapse, six months after completion of 
treatment. 
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Table 52: Blood pressure centile  in Overweight/ Obese children. 
 
Blood Pressure No. of children 
Systolic BP >90
th
 centile 1 
Systolic BP >95
th
 centile 2 
Diastolic BP >90
th
 centile 2 
Diastolic BP >95
th
 centile 2 
 
Two children each had systolic and diastolic BP> 95
th 
centile. In addition 10% (3/ 30) of  
children had SBP and DBP above the 90
th
 centile for age. 
The prevalence of hypertension (BP>95
th
 centile) = 13% (4/30). 
 
 
 
 
 
 
Table 53: Waist Circumference at follow up: 
 
WC >75
th
 Centile Frequency Percentage(%) 
No 3 10 
Yes 27 90 
Total 30 100 
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Figure 23:  Children with waist circumference >75
th
 centile: 
 
 
 
The above graph shows that 90% of the obese children had waist circumference more than 
75
th
 centile. 
Table 54: Lipid Profile: 
N = 30 
Lipids Number of Children Prevalence (%) 
Hypercholesterolemia 5 17 
Hyper Triglyceridemia 
 
4 13 
Low HDL 2 7 
High LDL 1 3 
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Figure 24: Dyslipidaemia 
 
 
 
Concurrent dyslipidaemia : 
2 children had both high cholesterol level and high triglyceride level 
1 child had elevated cholesterol and high LDL 
1 child had high triglyceride and low HDL level. 
 
Glycosylated Haemoglobin 
Two children (7%) had elevated HbA1C levels , however their fasting plasma glucose values 
were in the normal range.                  
 Glucose Insulin Ratio (GIR) : 
Six children (20%) had G/I ratio < 5 of which 4 were pre-pubertal and two were pubertal. 
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Table 55: GIR vs Tanner stage 
 
 
P=0.169 
Table 56: Correlation between Lipid profile and Waist Circumference(WC): 
Waist circumference>75
th
 centile- 90% (27/30) 
N = 27. 
 No. of children with 
WC>75
th
 centile(%) 
 
Hypercholesterolemia 5(19%) P =0.99 
Hypertrigylceridemia 4(15%) P =0.99 
Low HDL 2(7%) P =0.99 
High LDL 1(4%) P =0.99 
HbA1c 2(7%) P =0.99 
GIR 6(22%) P =0.99 
Parental BMI   
Father’s BMI 23(85%) P =0.24 
Mother’s BMI 24(89%) P =0.27 
  
 
Tanner stage Low GIR Normal GIR Total 
Stage 1 4(15%) 22 26 
Stage ≥ 2 2(33%) 2 4 
Total 6 24 30 
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Figure 25: Waist Circumference vs Lipid profile: 
 
 
 
Figure 26: Waist Circumference vs HbA1C, GIR and Parental BMI Centile: 
 
 
 
Correlation of waist circumference with lipid profile, HbA1c, GIR and parental BMI did not 
show statistical significance.  
99 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
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DISCUSSION 
 
We studied 241 children treated for acute Lymphoblastic leukaemia. Their clinical 
profile showed the following (i) male: female ratio was 7:3 (ii) mean age was 5.9 years 
(11months-15 years) (iii) 55% of the study population was <5years of age at the time of 
diagnosis. Gender ratio of our study group is tilted towards males, as was seen in an earlier 
publication from Chandy et al
47.
  The age distribution is similar to that reported by  Bachir et 
al
48
. 
Different types of ALL as per immunophenotype in our study showed Pre-B ALL 
81%, T-ALL 14%, Biphenotype ALL 3% and Pro-B ALL 2%. This distribution is similar to 
that is described in the literature.(48, 49).The incidence of CNS disease was 16%; with a 
higher incidence among those with T-ALL (38%) This appears to be much higher than 
several other studies (47,50) probably because only 30% of children treated in our unit was 
included for this study and hence it may not be a true representation. As per our risk 
stratification criteria, 1/3 rd had standard risk and 25% had high risk disease. Among those 
with T-ALL 65% had high risk disease and the remaining had intermediate risk disease.  
           Based on BMI, Children were stratified as under-nourished (UN), well-nourished 
(WN),over-weight (OW) and obese(Ob) using CDC BMI centile chart. The overweight and 
obese were grouped as a single group for further analysis. After excluding 14 children who 
were less than 2 years of age at diagnosis, therefore ineligible for analysis based on BMI, 227 
children were divided into various groups based on their nutrition. 44% of children were 
undernourished and 9% were overweight/obese. The prevalence of under nutrition and 
obesity in our study was comparable to that published by others, where 50% was 
undernourished and 8% were obese (6,8,34)  
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 Longitudinal assessment of nutritional status from diagnosis through treatment 
and post treatment follow up period 
195 children who had completed treatment and on follow up (mean 2.6 years, range 3 
months- 9.6 years) were included in this part of the analysis. We found a statistically 
significant trend towards increasing BMI from diagnosis through treatment and post 
treatment period (Table 26). 44% of children were under nourished at diagnosis and at the 
end of treatment only 13% remained under nourished. In contrast, the proportion of obese 
children went up from 7% at diagnosis to 29% at the end of treatment.  This change in BMI 
in our patients was statistically significant (p<0.05).  
           We further analysed the change in nutritional status at different time points. Change of 
BMI from beginning of induction to beginning of delayed intensification shows that 85 
children were undernourished at diagnosis, 32(38%) moved to the well-nourished group and 
2(2%) to the overweight/obese group. Of the 96 children who were well-nourished at 
diagnosis, 9(9%) moved to the overweight/obese group while 70(73%) remained in the same 
group. Nutritional change from beginning of induction to beginning of maintenance shows 
that 85 children were undernourished at diagnosis, 44(52%) moved to the well-nourished 
group and 5(6%) to the overweight/obese group. Of the 96 children who were well-nourished 
at diagnosis, 17(18%) moved to the overweight/obese group while 51(53%) remained in the 
same group. It was noted that the change in BMI in these patients was more towards the 
beginning of maintenance phase of chemotherapy. Various reports have shown similar trend, 
but significant weight gain was noted at various phases of treatment by others. 
   In a study by Withycomb et al 
10
 the author has looked at the weight patterns in 
children enrolled on CCG 1961 and found that successful treatment of higher risk childhood 
ALL was associated with excess weight gain from the beginning of maintenance therapy 
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through the end of the study. By the end of treatment 23% of patients were obese, compared 
to 14% at diagnosis. 
  Esbenshade et al
39
  found  increased in BMI from induction to consolidation, then a 
fall at the start of DI and a rise  in the early part of maintenance. It is important to serially 
monitor nutritional status of children for close monitoring and for necessary intervention.  
Zhang et al
38
 published a similar study done on 83 children. This was a retrospective 
cohort of 83 children diagnosed to have ALL between 1985-2010.BMI was assessed at 
different time points at diagnosis, end of induction, end of consolidation, very 6 months 
during treatment and yearly for up to 5 years post treatment. At diagnosis, 21% were 
overweight/obese, by the end of treatment and 5 years post-treatment, approximately 40% 
were overweight or obese. The mean BMI z-score increased significantly during induction ( P 
< 0.0001). It increased again during the first 6 months of maintenance ( P < 0.01). The study 
shows that high BMI z-score at diagnosis was associated with increased risk of being 
overweight/obese at treatment completion (OR = 2.9, 95% CI: 1.6-5.1). Weight gain during 
treatment was associated with being overweight/obese 5 years post-treatment (OR = 3.8, 95% 
CI: 1.1-12) 
          When we compared nutritional status of children at the end of treatment with that at 
annual follow up for the next 5 years, there was a significant increase in the number of 
obese/overweight children (p<0.05) from 7% to 35%.  There was also a significant reduction 
in number of under nourished from diagnosis (44%) compared to 5 years post treatment 
(15%)(Table 26 and Fig 12).Various other studies have followed children from diagnosis  and 
found there was increased prevalence of obesity on follow up after end of treatment (21-
25).However the sample size and the duration of follow up differed in each group.  
.  
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Impact of Nutritional Status on response to treatment  and outcome 
Several authors have found a significant difference in response to treatment, 
complications and overall survival between children in various nutritional groups (1-6, 14). 
The various  outcomes  parameters that were compared in our study were early response (day 
8 blast count), day 14 bone marrow, bone marrow remission at the end of induction, febrile 
neutropenia episodes, relapse and death.  
Begum et al 
2 
showed that number of days required to achieve induction remission in 
under nourished children was longer than the well- nourished group 39±0.72 Vs 31.63±0.17 
p<0.04. Rot et al 
4
 showed that the incidence of febrile neutropenia was significantly higher 
in the severely malnourished group mean being 3.8 Vs 1.42 p <0.001. Mendizabal et al 
1
showed that the relapses were more in the Bone marrow in undernourished than the well- 
nourished group which was 56% Vs 7% p < 0.0001. Similarly study by Buttirini et al 
6
 shows 
that relapse rate was higher in obese compared to non -obese children 26±2 Vs 20±0.6 (p 
=0.02).Arangure et al
14
 showed that death during initial phase of treatment was 2.6 times 
higher in malnourished than well nourished.  
In our study, on univariant analysis of response to prednisolone, day 14 bone marrow 
and end of induction bone marrow status, we did not find any difference between the thee 
nutritional groups (tables 27, 28 &29) Similarly, there was no significant difference in 
complications such as febrile neutropenia, relapse or death between the groups.  When we 
compared the number of children died in well nourished vs not well nourished, there seem to 
be a trend towards  higher mortality  in the non-well nourished group (66% vs 43%). The 
number of children in our study was less for multivariant analysis. 
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Screening for metabolic syndrome  in children who had completed treatment 
and reviewed during the study period  
Of the 195 children who successfully completed treatment for ALL, 114 were 
followed up in the outpatient clinic with respect to their nutritional status. Those who were 
overweight or obese were screened for various components of the metabolic syndrome. There 
were 78 boys and 36 girls in the group. Most of the children belonged to the age group of 1-5 
years. 
The mean age at diagnosis of ALL was 5.8 years (range 11 months to 14.3 years) and 
these children were reviewed at a mean period of 2.4 years (range 3 months to 9 years) after 
completion of treatment. 
 At follow up 71% of the children were well nourished while 4% were undernourished. 
Thirty out of the 114 children were overweight/obese. Thus the prevalence of obesity in this 
study was 26.3%. Most of the earlier studies have reported a 40-50% prevalence of obesity in 
children over a 5 year period after completion of ALL treatment (ref 17-20,38) 
It was interesting to compare the pattern of weight gain at follow up with the 
nutritional status at diagnosis and treatment completion. At diagnosis, 49% of children were 
undernourished. This group steadily gained weight with treatment and by follow up only 4% 
children remained undernourished. Similarly there was steady increase in BMI centile in the 
well nourished group from 51% at diagnosis to 81% at follow up. Those who were 
overweight at diagnosis remained the same. Other groups also have reported similar 
observations (38,39).In their study Zhang et al
38
 observed a close association between high 
BMI at diagnosis and  an increased risk of being overweight /obese at treatment completion. 
However in our study only 6% of the cohort were overweight/obese at diagnosis. Zhang et 
al
38
 also reported an increased risk of obesity post-treatment in those with greater weight gain 
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during treatment. Our results also show similar findings with most of the increments in BMI 
occurring during treatment and  no significant change in BMI from completion of treatment 
to follow up.(Table 26,p value <0.005,as in figure 18) 
           Esbenshade et al
39
 observed an increase in BMI during the induction phase of 
chemotherapy with its return to baseline values after induction followed by a steady increase 
over the subsequent phases of treatment . Majority of the children in our study gained weight 
steadily particularly during induction and delayed intensification phase. 
Of the 114 children on follow up, 30 were overweight/obese. There were 22 boys and 
8 girls in this group and their mean age at follow up was 10.3 years (range 6 - 15 years).  
Fourteen children were aged 6-10 year s and majority (24) were pre-pubertal. The mean 
duration between completion of treatment and follow up was 2.1 years (range-3 months to 9 
year ) . Mean BMI was 24.1kg/m
2  
(range 19.2 to 32.8).  
Analysis of the pattern of weight gain in these children also showed a very clear trend of 
steady weight gain early on in the treatment phase. Thus the prevalence of obesity increased 
exponentially from 20% at diagnosis to 73% at the beginning of maintenance phase and 93% by the 
end of treatment (Table 45 & Figure 19), Six children of this group who were undernourished at 
diagnosis gained weight steadily and all but one moved into the overweight category by the 
beginning of maintenance phase.  Those in the overweight/obese category at diagnosis remained so 
till follow up.  Similar findings were also reported by Withycombe et al 
10
wherein children who were 
obese at diagnosis had high BMI centile throughout treatment. 
Both extremes of weight (under-nourished and obese) are associated with poorer 
treatment outcome. Mejia et al
14
 reported a 2.6 times increased risk of mortality  during initial 
phase of treatment in the malnourished group as compared to the well -nourished group. 
Likewise Mendizabal et al reported disease free survival of 83% in children who were well 
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nourished at diagnosis as compared to 37% in those who were malnourished at diagnosis(1). 
They also reported higher bone marrow relapse rates in the malnourished group (56% Vs 7% 
(p< 0.0001). On the other hand in a large cohort of 4260 children treated for ALL,  Butturini 
et al
6
 reported lower 5 year event free survival as well as higher relapse rate in the obese  as 
compared to the non-obese  children aged above 10 years.   
Excessive weight gain in children treated for ALL is also multifactorial. The factors 
implicated in increased weight gain include cranial irradiation (especially dose≥ 18Gy), 
steroid use, growth hormone deficiency, chemo related complications and lifestyle changes. 
The role of leptin as well as premature adiposity rebound have also been documented in the 
mechanism of obesity. 
   In our study, only 6 children received cranial irradiation.. In contrast to other studies 
29-31, there was no correlation between cranial irradiation and obesity in our study. This may 
be due to the limited sample size. 
  Maximum dose of daily steroids is given during the induction and delayed 
intensification phase of ALL therapy. In addition children tend to be sedentary during the 
initial phases of treatment. These factors are likely to have contributed significantly to 
excessive weight gain early on during treatment. Thus five out of the six undernourished 
children in our study had become overweight by the completion of delayed intensification 
phase. In addition lifestyle (diet & physical activity) has a major role in obesity. Post-
treatment it is common for parents to be overprotective and restrict children’s outdoor 
activities. They also tend to over feed their children using high calorie food supplements.  
Although we did not have detailed dietary history or physical activity details during our 
analysis these factors also may have contributed to excessive weight gain during and after 
treatment.   
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  Growth hormone deficiency primarily affects linear growth causing a steady decrease 
in height velocity.83% of children in our study had their current height centile appropriate to 
or higher than the target height. Therefore it is unlikely that growth hormone deficiency 
contributed to the excessive weight gain in our cohort. The exponential increase in BMI is 
likely to have occurred between diagnosis and the beginning of maintenance phase. It is 
important to identify and modify factors that predispose to obesity during this phase of 
treatment.  
Overweight/obese children in our study were also screened for various risk factors for 
metabolic syndrome. 90% of the obese children had waist circumference> 75
th
 centile.. Waist 
circumference is is an indirect marker of abdominal obesity and is increasingly becoming an 
essential anthropometry in all obesity screening in the community.  In an elegant study 
published by Kurian R et al
41
 providing reference values for waist circumference in  urban 
Indian children, the authors suggest that the 75th percentile of waist circumference may be 
used as an “action point” to identify obesity and initiate early intervention. 
            
  In our study cohort, 13% (4/30) had hypertension (BP> 95
th 
centile). In addition 10% (3/ 30) 
of children had SBP and DBP above the 90
th
 centile for age. Esbenshade et al
39
 reported a high 
prevalence of hypertension during ALL treatment (.41.5% systolic hypertension and 24% with 
diastolic hypertension). There was also high prevalence of pre-hypertension. Although there was no 
significant hypertension in our cohort.it is important to follow them long term preferably using 
ambulatory blood pressure monitor. The excursions of blood pressure as well as absence of nocturnal 
dip are known to be associated with long term morbidity rather than blood pressure reading at one 
point of time. 6 children in our cohort had glucose/insulin ratio < 5 suggestive of some degree of 
insulin resistance, interestingly, four of them were pre-pubertal. The prevalence of dyslipidaemia was 
27%(8/30)  % and 7%(2/30) abnormal glycosylated haemoglobin. levels. There was no correlation 
108 
 
between waist circumference and other parameters such as fasting  lipids, blood sugar, 
glucose/insulin ratio  and parental BMI  in our study. Absence of significant metabolic abnormalities 
is most likely due to the limited sample size and the younger age of our study cohort (<16 years). 
      Thus it is clear that excessive weight at diagnosis or excessive weight gain during 
treatment are unlikely to be reversed. As age advances the risk of metabolic syndrome 
becomes higher in those who are obese. All children in our follow-up group were under 15 
years of age. Insulin resistance which is the primary metabolic abnormality in all the 
components of metabolic syndrome takes several years to manifest as clinical diseases such 
as type2 diabetes, hypertension etc. Therefore these children need long term follow up. 
Obesity is the most important environmental factor which amplifies insulin resistance. Simple 
measures such as measuring waist circumference in the clinic may go a long way in 
identifying children at risk for overweight. Early intervention includes recommendation of 
lifestyle changes in families with obese children. 
One of the major limitations of our study was small sample size. In addition, 
considering the fact that Indian children may develop metabolic abnormalities at much lower 
BMI levels as compared to the rest of the world, we do not have metabolic data on the 84 
children who were not obese at follow-up.   
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SUMMARY  
 
 241 children treated for Acute Lymphoblastic Leukaemia (ALL) were included in this 
study on longitudinal assessment of nutritional status from diagnosis, through 
treatment and post treatment period using BMI charts.  
 At diagnosis, 44% of children were under nourished, 47 % were well nourished and 
9% were overweight/ obese. At end of treatment 13% were undernourished and 29% 
were obese. While there was a significant reduction in the number of children in the 
under nourished group, the proportion of obese children increased significantly from 
7% at diagnosis to 29% at the end of treatment. This was  statistically 
significant(p<0.05) 
 The impact of nutritional status on treatment response and outcome did not show 
statistical significance. 
 114 children were reviewed during this study period; 30(26%) overweight/obese 
children were identified.  Only 20 % of this group was obese at diagnosis, which 
increased to 73% at the beginning of maintenance and 93% by the end of treatment. 
Six children in this group moved from under nourished at diagnosis to overweight  
end of treatment. This group was further screened for metabolic syndrome. The 
prevalence of hypertension was 13%, dyslipidaemia was 27% and glucose intolerance 
was 7% in the above study group. 
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CONCLUSIONS &  RECOMMENDATIONS 
Nutritional status of children treated for ALL change from diagnosis, through 
treatment and post treatment period. In our study, it was encouraging to note that the 
prevalence of under nutrition reduced considerably as they went through treatment. It was 
also interesting to find that a significant proportion of well-nourished children became obese 
by the end of their treatment. In this group of obese/overweight children many had 
hypertension, dyslipidaemia and glucose intolerance.  
Therefore, we recommend that nutritional status of children on treatment for acute 
lymphoblastic leukaemia be monitored closely during and after treatment.  Appropriate and 
timely intervention should be implemented to provide good quality life for them.  Early signs 
of metabolic syndrome should be addressed and lifestyle modification should be suggested. 
Nutritional interventions should be an integral part of “Fit-for-life” programs for children 
with cancer. 
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LIMITATIONS 
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LIMITATIONS 
 
 This study included only a third of our patients with ALL, due to short duration of 
time available for the study. Therefore the sample size required for comparison of 
various outcome parameters between different nutritional groups could not be done. 
 
 Clinical and biochemical profile of non-obese/overweight children were not included 
for comparison. 
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Annexure 1 : Treatment protocol 
 Pre Induction- Day 1-7  
Dexamethasone  IV 6mg/m2 Day 1& 2 
Prednisolone   PO 60mg/m2 Day 3-7 in 2 doses 
Induction : day 8-29 
 
Protocol for ALL children for Standard risk.(SR) 
Induction- Day 8 count is mandatory for all patients. 
Prednisolone  PO 60mg/m2 Day 8-29 & taper over 1 week 
Vincristine IV         1.5mg/m2 on D 8, 15, 22, 29 
Daunorubicin IV 30mg/m2 on D 8, 15, 22, 29  
L-Asparaginase IM 10,000 iu /m2 x 9 doses 
Methotrexate  IT D 1 & 8 
Consolidation 
Cyclophosphamide IV 1000mg/m2 on Day 1 & 21 
Cytarabine SC/IV-            75mg/m2 16 doses on days 1-4, 8-11, 15-18, 22-25 
Methotrexate IT         12mgdays 1, 8, 15, 22 
6Mercaptopurine       PO 60mg/m2 daily for   4 weeks  
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Radiotherapy was started after completing Consolidation(18 Gy for those with definite CNS 
disease / 12Gy for those with traumatic CSF 24 Gy for overt testicular disease at diagnosis 
which is persisting) 
 
Interim Maintenance  
Vincristine   IV 1.5mg/m2 on day 1 & 29 
Dexamethasone  PO 6mg/m2/day x 5 days week 1 &5 
Methotrexate   IT  on day 1 & 29 
6 Mercaptopurine  PO 75mg/m2 daily for 8 weeks 
Methotrexate   PO 20mg/m2 weekly for 8 weeks on Wednesdays  
 
Delayed Intensification 
 Phase 1( Reinduction) 
Vincristine   IV 1.5 mg/m2 on Days 1, 8, 15 
Adriamycin   IV 30mg/m2 on Days 1, 8, 15 
L-Asparaginase   IM 10,000 iu /m2/d on Days 1, 4, 7, 11 
Inj Methotrexate  IT 12mg on day 1 & 18 
T. Dexamethasone  PO 10mg/m2 on weeks 1 &3 
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Phase 2(Reconsolidation) 
Cyclophosphamide   IV 1000mg/m2 Day 1 
Cytarabine SC/IM          75mg/m2 Day 1-4, 8-11 
6-Thioguanine  PO 60mg/m2  daily for 2 weeks 
 
Maintenance   (2years for girls and 2 ½ years for boys) 
Vincristine   IV 1.5mg/m2 monthly  
Dexamethasone  PO 6mg/m2 for 5 days every month 
Methotrexate   IT  once in 12 weeks 
6 Mercaptopurine  PO 75mg/m2 daily  
Methotrexate   PO 20mg/m2 weekly  
ALL treatment protocol for  IR & HR (Intermediate and high risk) 
ALL - IR would receive two intensification blocks  
ALL- HR (where BMT is not an option) 
Induction   4 Drug induction as per standard protocol 
Consolidation  3 drug + triple IT Methotrexate 
Followed by 18Gy cranial RT / 4 courses of HD Methotrexate 
Escalating Capizzi Maintenance/ 4 courses of HD Mehtotrexate 
Vincristine 1.5 mg/m2 on days  2, 12, 22, 32 & 42 
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2.Proforma: 
NAME: ………………………………………………………….                          
HOSPITAL NO: …………………………………….. 
DATE OF BIRTH    
SEX:            Male    Female  
AGE OF DIAGNOSIS                   Yrs           
DATE OF DIAGNOSIS:  
DIAGNOSIS :  
1. PRE B ALL 
2. T CELL ALL 
3. BIPHENOTYPIC ALL 
4. OTHERS  
DURATION OF SYMPTOMS:  
1. Days 
2. Months 
SYMPTOMS  
1. Fever  2.  Respiratory system 
3. Bone Pain  4.  Pallor 
5. Fatigue  6.  Bleeding 
7. Neck Swelling 8.  Abdominal distension ± Pain 
9. Loss of Apetite 10.  Weight Loss 
11. Others 
EXAMINATION  
1. Pallor  2.  Icterus 
3. Edema  4.  Bleeding Signs 
5. Hepatomegaly 6.  Splenomegaly 
 
LYMPHADENOPATHY:  
1. YES 
2. NO 
131 
 
 If YES :  
1. Cervical 
2. Axillary 
3. Inguinal  
INVESTIGATIONS AT DIAGNOSIS: - 
 Hb    - 
 WBC    - 
 PLATELETS   - 
 BLASTS IN THE PERIPHERY - 
 BONE MARROW BLAST - 
 
CNS DISEASE   
1. Positive 
2. Negative 
 
TESTES               1.    Involved 
                    2.    Not Involved 
IPT    
1. PRE B ALL 
2. T CELL ALL 
3. BIPHENOTYPIC 
4. OTHERS 
 
RTPCR   1.     Done 
   2.     Not Done 
     Hyperploidy          
CYTOGENETICS 1.   Done 
     Hypoploidy 
 
   2.  Not Done 
RISK STRATIFICATION:  
1. Standard 
2. Intermediate 
3. High 
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TUMOUR LYSIS:   
1. Present 
2. Absent 
DAY 8   
WBC  -   
BLAST  - 
BLAST COUNT - 
DAY 14  
  BONE MARROW BLAST   - 
 
END OF INDUCTION BONE MARROW IN  
1.  Remission 
2.  Not In Remission 
NO. OF DI 
1. One 
2. Two 
CRANIAL RT    
1. Given 
2. Not Given 
 
DATE OF COMPLETION OF TREATMENT: 
Details of Febrile Neutropenia requiring adneuseone 
No. of Episodes   
Episodes No:  
Lower ANC:  
No. of days Hospitalised 
ANTIBIOTICS 
1) 1ST LINE 
2) 2ND LINE 
3) HIGHER THAN 2ND LINE 
4) ANTIFUNGALS 
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BLOOD CULTURE                              Positive 
                                             Negative  
If positive name of the organism isolated ________________________________ 
Any Swab Culture                              Positive       
If done                                                            Negative 
 
Episodes of Febrile Neutropenia in each phase of chemotherapy 
Induction                                  Consolidation     interim Maintenance    
Delayed intensification                  Maintenance    
 At Diagnosis At Day 1 of DI-1 At Day 1 of Maint. End of Rx 
Weight (kg)     
Height (cm)     
BMI     
BMI Centile     
<5%     
5-85%     
>85% but <95%     
>95%     
Nutritional Groups     
Under Nourished     
Well Nourished     
Overweight/Obese     
Date of completion of Rx  
 
Post Treatment HBsAg             Positive 
                                                                     Negative 
  ECHO          EF%           ________ 
1 2 
1 
2 
1 
2 
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          FS%          ________   
OUTCOME:   Relapse                        Yes 
                                                                    No 
 
If YES site of relapse                               Blood 
                                                          Bone Marrow 
                                                                    Testis 
                                                                    CNS  
TIME OF RELAPSE                                    During Treatment 
                                                                     Post Treatment 
 
2nd RELAPSE                                  1.      YES 
                2.       NO 
IF 2nd RELAPSE SITE OF RELAPSE 1.    Bone Marrow 
     2.     Testes  
     3.      CNS  
FOLLOW UP AFTER TREATMENT 
Month/Years after completion of Rx      
Wt      
Ht      
BMI      
BMI CENTILE      
<5%      
5-85%      
>85% but <95%      
1 
2
12 
3 
4
1 
2 
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>95%      
Nutritional Groups      
Under Nourished      
Well Nourished      
Overweight/Obese      
 
POST TREATMENT                                    Months after treatment 
                                                                      Years after treatment 
 
DEATH                                                    Yes   
                                                         No 
 
If YES  1.    During Treatment 
  2.     Post Treatment   
 
  
If During Treatment –phase of Rx 1 INDUCTION 
2. CONSOLIDATION 
3.  IM1 
4. DI1 PH1 
5. DI1 PH2 
6. IM2 
7. DI2 PH1 
8. DI2 PH2 
9. MAINTENANCE 
 
 
 
1 
2 
1 
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SECOND MALIGNANCY                             Yes 
                                                                       No 
 
 
PROFORMA 
PART II 
Last Follow-up Visit date:  
No. of months after completion of treatment _________ 
Weight  
Height  
BMI  
 
BMI PERCENTILE 
<5%  
5-85%  
>85% BUT <95%  
>95%  
Waist Circumference (cm) 
Blood Pressure (mm HG) 
Blood Pressure >90% for height for age – Yes / No 
Tanner Stage 
TANNER stage Breast  / Genitalia Pubic Hair 
1.   
2.   
3.   
4.   
5.   
 
 
2 
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Acanthosis nigricans Present / Absent 
 
Lipid profile 
Total Cholesterol  
Triglyceride  
HDL  
LDL  
 
Fasting Blood Sugar 
HbA1c 
Fasting insulin level 
PARENTS DATA 
 Fathers Data Mother’s Data 
Weight   
Height   
BMI   
 
Diet – Overeating / Normal / under –eating 
Physical activity – Sedentary (TV/Indoor) / Active (outdoor/exercise)/ both 
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3.Information sheet in English: 
 
 
 PATIENT INFORMATION SHEET  
 
 
This information sheet will explain to you the details regarding the present  
study. Kindly go through this carefully. You are free to clear your doubts before  
consenting to participate in this study.  
 
TITLE OF RESEARCH:  
Longitudinal assessment of nutritional status and its effects on the outcome of children 
completed treatment for Acute Lymphoblastic Leukemia.  
 
PERSON CARRYING OUT RESEARCH: Dr. R. Magdalenal  
 
I’m Dr.R.Magdalenal , a PG registrar working in the department of paediatrics ,  
CMC Vellore. I am doing a study on the effect of nutritional status of children  
treated for blood cancer. Details of the study are given below. I would like you to be part of 
this study, but the choice is yours; you can decide not to take part in this study. I am happy to 
clarify your doubts, if there are any.  
This study will be done in children who have completed treatment for Acute 
Lymphoblastic Leukaemia, a type of blood cancer. It is known from other studies that 
nutritional status ( weight and height) at diagnosis and through treatment has an effect on the 
outcome. The well nourished children have better outcome than those who are under weight 
or over weight. We wilI collect the weight and height of your child at diagnosis and during 
treatment from their hospital record and look at the effect of that on their response to 
treatment.  
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Some children with leukaemia have a tendency to put on too much weight, especially 
after completion of treatment. It is known that if they remain over weight, they are likely to 
develop some complications such as high blood pressure, diabetes, high cholesterol and heart 
problems at an early age. It is recommended that children with overweight should be checked 
for these complications and appropriate measures to be taken to prevent or delay these 
complications. Second part of my study is to check blood pressure, blood sugar, insulin levels 
and cholesterol in those who are overweight. These tests have been regularly done for 
children during their follow up visits. 5-8ml of blood will be collected from each child to do 
these tests during their follow up visit. I will also be checking waist circumference of 
children, as it is a good indicator of obesity.  
 
CONFIDENTIALITY:  
 
Your name will not be mentioned anywhere neither in the data sheet nor in the final 
published study. Your data will bear a study number and the number will be used till analysis. 
The master sheet will have your study number  
 
SHARING OF THE RESULT:  
 
The results of research are property of Christian medical college and I'm entitled to 
publish it in a journal or present in a conference.  
This proposal has been reviewed and approved by [IRB, Christian Medical College], which is 
a committee whose task it is to make sure that research participants are protected from harm. 
If you wish to find more about the IRB,  
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Contact  
Research Office,  
Second floor, Carman block,  
Christian Medical College,  
Bagayam, Vellore 632002.  
Email: research@cmcvellore.ac.in, Telephone: 04162284294.  
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It has also been reviewed by the Ethics Review Committee CMC Vellore, which is 
supporting the study.  
In case of doubts or questions, please contact Dr.R.Magdalenal.  
Department of Paediatrics, Christian Medical College and Hospital, Vellore. 
Ph.No.9443040411  
PART II: Certificate of Consent  
I have read the foregoing information/ it has been read to me. I have had the opportunity to 
ask questions about it and any questions that I have asked have been answered to my 
satisfaction. I consent voluntarily to participate as a participant in this research.  
Print Name of Participant__________________ 
Signature of Participant ___________________             
Date ___________________________                             
Day/month/year                                                                                    
If illiterate Thumb impression (R / L)  
I have witnessed the accurate reading of the consent form to the potential participant, and the 
individual has had the opportunity to ask questions. I confirm that the individual has given 
consent freely.  
Print name of witness_____________________       and     Thumb print of  
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participant 
Signature of witness ______________________ 
Date ________________________ 
Day/month/year  
Statement by the researcher/person taking consent 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that the following will be done: 
1. Data regarding weight and height will be taken from OP chart. 
2. .Blood test -for lipid levels ,fasting insulin and blood glucose 
3. Waist circumference measurement. 
4. Participation is voluntary and cost of blood test will be borne by the research fund. 
I confirm that the participant was given an opportunity to ask questions about the study, and 
all the questions asked by the participant have been answered correctly and to the best of my 
ability. I confirm that the individual has not been coerced into giving consent, and the consent 
has been given freely and voluntarily.  
A copy of this ICF has been provided to the participant. 
Print Name of Researcher/person taking the consent-Dr.R.Magdalenal 
Signature of Researcher /person taking the consent__________________________ 
Date ___________________________ 
. 
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4.Tamil information sheet:  
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5. English consent form: 
 Informed Consent Form for Subjects  
Informed Consent form to participate in a research study  
 
Study Title: Longitudinal assessment of nutritional status and its effects on the outcome of 
children completed treatment for Acute Lymphoblastic Leukemia.  
 
Study Number: ____________  
Subject’s Initials: __________________ Subject’s Name: 
_________________________________________  
Date of Birth / Age: ___________________________  
(Subject’s parent)  
 
(i) I confirm that I have read and understood the information sheet dated ____________ for 
the above study and have had the opportunity to ask questions.  
 
(ii) I understand that my baby’s participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal rights 
being affected.  
 
(iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s behalf, 
the Ethics Committee and the regulatory authorities will not need my permission to look at 
the health records of my baby both in respect of the current study and any further research 
that may be conducted in relation to it, even if I withdraw from the trial. I agree to this access. 
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However, I understand that identity of my baby will not be revealed in any information 
released to third parties or published.  
 
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s).  
 
(v) I agree to take part in the above study.  
 
(vi) I am aware of the Audio-visual recording of the Informed Consent.  
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/______  
Signatory’s Name: _________________________________ Signature:  
Or Representative: _________________  
Date: _____/_____/______  
 
Signatory’s Name: _________________________________  
 
Signature of the Investigator: ________________________  
Date: _____/_____/______  
Study Investigator’s Name: _________________________  
Signature of the Witness: ___________________________  
Date: _____/_____/_______  
Name & Address of the Witness: ______________________________ 
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